CINXE.COM

<!DOCTYPE html> <html class="client-nojs vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-sticky-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-1 vector-feature-night-mode-enabled skin-theme-clientpref-day vector-toc-available" lang="en" dir="ltr"> <head> <meta charset="UTF-8"> <title>Atezolizumab - Wikipedia</title> <script>(function(){var className="client-js vector-feature-language-in-header-enabled vector-feature-language-in-main-page-header-disabled vector-feature-sticky-header-disabled vector-feature-page-tools-pinned-disabled vector-feature-toc-pinned-clientpref-1 vector-feature-main-menu-pinned-disabled vector-feature-limited-width-clientpref-1 vector-feature-limited-width-content-enabled vector-feature-custom-font-size-clientpref-1 vector-feature-appearance-pinned-clientpref-1 vector-feature-night-mode-enabled skin-theme-clientpref-day vector-toc-available";var cookie=document.cookie.match(/(?:^|; )enwikimwclientpreferences=([^;]+)/);if(cookie){cookie[1].split('%2C').forEach(function(pref){className=className.replace(new RegExp('(^| )'+pref.replace(/-clientpref-\w+$|[^\w-]+/g,'')+'-clientpref-\\w+( |$)'),'$1'+pref+'$2');});}document.documentElement.className=className;}());RLCONF={"wgBreakFrames":false,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy", "wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ff965d3e-28a7-4be4-82b4-39bde340ca26","wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Atezolizumab","wgTitle":"Atezolizumab","wgCurRevisionId":1248728230,"wgRevisionId":1248728230,"wgArticleId":46868318,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Source attribution","Articles with short description","Short description matches Wikidata","Use American English from August 2020","All Wikipedia articles written in American English","Use dmy dates from September 2024","Drugs with non-standard legal status","Chemicals that do not have a ChemSpider ID assigned","Articles without EBI source","Articles without InChI source","Articles containing unverified chemical infoboxes","Drugs that are a monoclonal antibody", "All articles with unsourced statements","Articles with unsourced statements from August 2020","Articles containing potentially dated statements from 2016","All articles containing potentially dated statements","Wikipedia articles in need of updating from March 2020","All Wikipedia articles in need of updating","Drugs developed by Genentech","Drugs developed by Hoffmann-La Roche","Monoclonal antibodies for tumors","Orphan drugs"],"wgPageViewLanguage":"en","wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Atezolizumab","wgRelevantArticleId":46868318,"wgIsProbablyEditable":true,"wgRelevantPageIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgNoticeProject":"wikipedia","wgCiteReferencePreviewsActive":false,"wgFlaggedRevsParams":{"tags":{"status":{"levels":1}}},"wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wgPopupsFlags":0,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks": "en"},"wgMFDisplayWikibaseDescriptions":{"search":true,"watchlist":true,"tagline":false,"nearby":true},"wgWMESchemaEditAttemptStepOversample":false,"wgWMEPageLength":40000,"wgRelatedArticlesCompat":[],"wgCentralAuthMobileDomain":false,"wgEditSubmitButtonLabelPublish":true,"wgULSPosition":"interlanguage","wgULSisCompactLinksEnabled":false,"wgVector2022LanguageInHeader":true,"wgULSisLanguageSelectorEmpty":false,"wgWikibaseItemId":"Q20707748","wgCheckUserClientHintsHeadersJsApi":["brands","architecture","bitness","fullVersionList","mobile","model","platform","platformVersion"],"GEHomepageSuggestedEditsEnableTopics":true,"wgGETopicsMatchModeEnabled":false,"wgGEStructuredTaskRejectionReasonTextInputEnabled":false,"wgGELevelingUpEnabledForUser":false};RLSTATE={"ext.globalCssJs.user.styles":"ready","site.styles":"ready","user.styles":"ready","ext.globalCssJs.user":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.vector.search.codex.styles":"ready", "skins.vector.styles":"ready","skins.vector.icons":"ready","jquery.makeCollapsible.styles":"ready","ext.wikimediamessages.styles":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.uls.interlanguage":"ready","wikibase.client.init":"ready","ext.wikimediaBadges":"ready"};RLPAGEMODULES=["ext.cite.ux-enhancements","mediawiki.page.media","site","mediawiki.page.ready","jquery.makeCollapsible","mediawiki.toc","skins.vector.js","ext.centralNotice.geoIP","ext.centralNotice.startUp","ext.gadget.ReferenceTooltips","ext.gadget.switcher","ext.urlShortener.toolbar","ext.centralauth.centralautologin","mmv.bootstrap","ext.popups","ext.visualEditor.desktopArticleTarget.init","ext.visualEditor.targetLoader","ext.echo.centralauth","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","ext.uls.interface","ext.cx.eventlogging.campaigns","ext.cx.uls.quick.actions","wikibase.client.vector-2022","ext.checkUser.clientHints","ext.quicksurveys.init", "ext.growthExperiments.SuggestedEditSession","wikibase.sidebar.tracking"];</script> <script>(RLQ=window.RLQ||[]).push(function(){mw.loader.impl(function(){return["user.options@12s5i",function($,jQuery,require,module){mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"}); }];});});</script> <link rel="stylesheet" href="/w/load.php?lang=en&modules=ext.cite.styles%7Cext.uls.interlanguage%7Cext.visualEditor.desktopArticleTarget.noscript%7Cext.wikimediaBadges%7Cext.wikimediamessages.styles%7Cjquery.makeCollapsible.styles%7Cskins.vector.icons%2Cstyles%7Cskins.vector.search.codex.styles%7Cwikibase.client.init&only=styles&skin=vector-2022"> <script async="" src="/w/load.php?lang=en&modules=startup&only=scripts&raw=1&skin=vector-2022"></script> <meta name="ResourceLoaderDynamicStyles" content=""> <link rel="stylesheet" href="/w/load.php?lang=en&modules=site.styles&only=styles&skin=vector-2022"> <meta name="generator" content="MediaWiki 1.44.0-wmf.4"> <meta name="referrer" content="origin"> <meta name="referrer" content="origin-when-cross-origin"> <meta name="robots" content="max-image-preview:standard"> <meta name="format-detection" content="telephone=no"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Atezolizumab_PD-L1_5X8L.png/1200px-Atezolizumab_PD-L1_5X8L.png"> <meta property="og:image:width" content="1200"> <meta property="og:image:height" content="1200"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Atezolizumab_PD-L1_5X8L.png/800px-Atezolizumab_PD-L1_5X8L.png"> <meta property="og:image:width" content="800"> <meta property="og:image:height" content="800"> <meta property="og:image" content="https://upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Atezolizumab_PD-L1_5X8L.png/640px-Atezolizumab_PD-L1_5X8L.png"> <meta property="og:image:width" content="640"> <meta property="og:image:height" content="640"> <meta name="viewport" content="width=1120"> <meta property="og:title" content="Atezolizumab - Wikipedia"> <meta property="og:type" content="website"> <link rel="preconnect" href="//upload.wikimedia.org"> <link rel="alternate" media="only screen and (max-width: 640px)" href="//en.m.wikipedia.org/wiki/Atezolizumab"> <link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Atezolizumab&action=edit"> <link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"> <link rel="icon" href="/static/favicon/wikipedia.ico"> <link rel="search" type="application/opensearchdescription+xml" href="/w/rest.php/v1/search" title="Wikipedia (en)"> <link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"> <link rel="canonical" href="https://en.wikipedia.org/wiki/Atezolizumab"> <link rel="license" href="https://creativecommons.org/licenses/by-sa/4.0/deed.en"> <link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&feed=atom"> <link rel="dns-prefetch" href="//meta.wikimedia.org" /> <link rel="dns-prefetch" href="//login.wikimedia.org"> </head> <body class="skin--responsive skin-vector skin-vector-search-vue mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Atezolizumab rootpage-Atezolizumab skin-vector-2022 action-view"><a class="mw-jump-link" href="#bodyContent">Jump to content</a> <div class="vector-header-container"> <header class="vector-header mw-header"> <div class="vector-header-start"> <nav class="vector-main-menu-landmark" aria-label="Site"> <div id="vector-main-menu-dropdown" class="vector-dropdown vector-main-menu-dropdown vector-button-flush-left vector-button-flush-right" > <input type="checkbox" id="vector-main-menu-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-main-menu-dropdown" class="vector-dropdown-checkbox " aria-label="Main menu" > <label id="vector-main-menu-dropdown-label" for="vector-main-menu-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-menu mw-ui-icon-wikimedia-menu"></span> <span class="vector-dropdown-label-text">Main menu</span> </label> <div class="vector-dropdown-content"> <div id="vector-main-menu-unpinned-container" class="vector-unpinned-container"> <div id="vector-main-menu" class="vector-main-menu vector-pinnable-element"> <div class="vector-pinnable-header vector-main-menu-pinnable-header vector-pinnable-header-unpinned" data-feature-name="main-menu-pinned" data-pinnable-element-id="vector-main-menu" data-pinned-container-id="vector-main-menu-pinned-container" data-unpinned-container-id="vector-main-menu-unpinned-container" > <div class="vector-pinnable-header-label">Main menu</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-main-menu.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-main-menu.unpin">hide</button> </div> <div id="p-navigation" class="vector-menu mw-portlet mw-portlet-navigation" > <div class="vector-menu-heading"> Navigation </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="n-mainpage-description" class="mw-list-item"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"><span>Main page</span></a></li><li id="n-contents" class="mw-list-item"><a href="/wiki/Wikipedia:Contents" title="Guides to browsing Wikipedia"><span>Contents</span></a></li><li id="n-currentevents" class="mw-list-item"><a href="/wiki/Portal:Current_events" title="Articles related to current events"><span>Current events</span></a></li><li id="n-randompage" class="mw-list-item"><a href="/wiki/Special:Random" title="Visit a randomly selected article [x]" accesskey="x"><span>Random article</span></a></li><li id="n-aboutsite" class="mw-list-item"><a href="/wiki/Wikipedia:About" title="Learn about Wikipedia and how it works"><span>About Wikipedia</span></a></li><li id="n-contactpage" class="mw-list-item"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia"><span>Contact us</span></a></li> </ul> </div> </div> <div id="p-interaction" class="vector-menu mw-portlet mw-portlet-interaction" > <div class="vector-menu-heading"> Contribute </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="n-help" class="mw-list-item"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia"><span>Help</span></a></li><li id="n-introduction" class="mw-list-item"><a href="/wiki/Help:Introduction" title="Learn how to edit Wikipedia"><span>Learn to edit</span></a></li><li id="n-portal" class="mw-list-item"><a href="/wiki/Wikipedia:Community_portal" title="The hub for editors"><span>Community portal</span></a></li><li id="n-recentchanges" class="mw-list-item"><a href="/wiki/Special:RecentChanges" title="A list of recent changes to Wikipedia [r]" accesskey="r"><span>Recent changes</span></a></li><li id="n-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_upload_wizard" title="Add images or other media for use on Wikipedia"><span>Upload file</span></a></li> </ul> </div> </div> </div> </div> </div> </div> </nav> <a href="/wiki/Main_Page" class="mw-logo"> <img class="mw-logo-icon" src="/static/images/icons/wikipedia.png" alt="" aria-hidden="true" height="50" width="50"> <span class="mw-logo-container skin-invert"> <img class="mw-logo-wordmark" alt="Wikipedia" src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" style="width: 7.5em; height: 1.125em;"> <img class="mw-logo-tagline" alt="The Free Encyclopedia" src="/static/images/mobile/copyright/wikipedia-tagline-en.svg" width="117" height="13" style="width: 7.3125em; height: 0.8125em;"> </span> </a> </div> <div class="vector-header-end"> <div id="p-search" role="search" class="vector-search-box-vue vector-search-box-collapses vector-search-box-show-thumbnail vector-search-box-auto-expand-width vector-search-box"> <a href="/wiki/Special:Search" class="cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only search-toggle" title="Search Wikipedia [f]" accesskey="f"><span class="vector-icon mw-ui-icon-search mw-ui-icon-wikimedia-search"></span> <span>Search</span> </a> <div class="vector-typeahead-search-container"> <div class="cdx-typeahead-search cdx-typeahead-search--show-thumbnail cdx-typeahead-search--auto-expand-width"> <form action="/w/index.php" id="searchform" class="cdx-search-input cdx-search-input--has-end-button"> <div id="simpleSearch" class="cdx-search-input__input-wrapper" data-search-loc="header-moved"> <div class="cdx-text-input cdx-text-input--has-start-icon"> <input class="cdx-text-input__input" type="search" name="search" placeholder="Search Wikipedia" aria-label="Search Wikipedia" autocapitalize="sentences" title="Search Wikipedia [f]" accesskey="f" id="searchInput" > <span class="cdx-text-input__icon cdx-text-input__start-icon"></span> </div> <input type="hidden" name="title" value="Special:Search"> </div> <button class="cdx-button cdx-search-input__end-button">Search</button> </form> </div> </div> </div> <nav class="vector-user-links vector-user-links-wide" aria-label="Personal tools"> <div class="vector-user-links-main"> <div id="p-vector-user-menu-preferences" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <div id="p-vector-user-menu-userpage" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <nav class="vector-appearance-landmark" aria-label="Appearance"> <div id="vector-appearance-dropdown" class="vector-dropdown " title="Change the appearance of the page's font size, width, and color" > <input type="checkbox" id="vector-appearance-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-appearance-dropdown" class="vector-dropdown-checkbox " aria-label="Appearance" > <label id="vector-appearance-dropdown-label" for="vector-appearance-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-appearance mw-ui-icon-wikimedia-appearance"></span> <span class="vector-dropdown-label-text">Appearance</span> </label> <div class="vector-dropdown-content"> <div id="vector-appearance-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <div id="p-vector-user-menu-notifications" class="vector-menu mw-portlet emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> <div id="p-vector-user-menu-overflow" class="vector-menu mw-portlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-sitesupport-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en" class=""><span>Donate</span></a> </li> <li id="pt-createaccount-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:CreateAccount&returnto=Atezolizumab" title="You are encouraged to create an account and log in; however, it is not mandatory" class=""><span>Create account</span></a> </li> <li id="pt-login-2" class="user-links-collapsible-item mw-list-item user-links-collapsible-item"><a data-mw="interface" href="/w/index.php?title=Special:UserLogin&returnto=Atezolizumab" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o" class=""><span>Log in</span></a> </li> </ul> </div> </div> </div> <div id="vector-user-links-dropdown" class="vector-dropdown vector-user-menu vector-button-flush-right vector-user-menu-logged-out" title="Log in and more options" > <input type="checkbox" id="vector-user-links-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-user-links-dropdown" class="vector-dropdown-checkbox " aria-label="Personal tools" > <label id="vector-user-links-dropdown-label" for="vector-user-links-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-ellipsis mw-ui-icon-wikimedia-ellipsis"></span> <span class="vector-dropdown-label-text">Personal tools</span> </label> <div class="vector-dropdown-content"> <div id="p-personal" class="vector-menu mw-portlet mw-portlet-personal user-links-collapsible-item" title="User menu" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-sitesupport" class="user-links-collapsible-item mw-list-item"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&utm_medium=sidebar&utm_campaign=C13_en.wikipedia.org&uselang=en"><span>Donate</span></a></li><li id="pt-createaccount" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:CreateAccount&returnto=Atezolizumab" title="You are encouraged to create an account and log in; however, it is not mandatory"><span class="vector-icon mw-ui-icon-userAdd mw-ui-icon-wikimedia-userAdd"></span> <span>Create account</span></a></li><li id="pt-login" class="user-links-collapsible-item mw-list-item"><a href="/w/index.php?title=Special:UserLogin&returnto=Atezolizumab" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o"><span class="vector-icon mw-ui-icon-logIn mw-ui-icon-wikimedia-logIn"></span> <span>Log in</span></a></li> </ul> </div> </div> <div id="p-user-menu-anon-editor" class="vector-menu mw-portlet mw-portlet-user-menu-anon-editor" > <div class="vector-menu-heading"> Pages for logged out editors <a href="/wiki/Help:Introduction" aria-label="Learn more about editing"><span>learn more</span></a> </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="pt-anoncontribs" class="mw-list-item"><a href="/wiki/Special:MyContributions" title="A list of edits made from this IP address [y]" accesskey="y"><span>Contributions</span></a></li><li id="pt-anontalk" class="mw-list-item"><a href="/wiki/Special:MyTalk" title="Discussion about edits from this IP address [n]" accesskey="n"><span>Talk</span></a></li> </ul> </div> </div> </div> </div> </nav> </div> </header> </div> <div class="mw-page-container"> <div class="mw-page-container-inner"> <div class="vector-sitenotice-container"> <div id="siteNotice"></div> </div> <div class="vector-column-start"> <div class="vector-main-menu-container"> <div id="mw-navigation"> <nav id="mw-panel" class="vector-main-menu-landmark" aria-label="Site"> <div id="vector-main-menu-pinned-container" class="vector-pinned-container"> </div> </nav> </div> </div> <div class="vector-sticky-pinned-container"> <nav id="mw-panel-toc" aria-label="Contents" data-event-name="ui.sidebar-toc" class="mw-table-of-contents-container vector-toc-landmark"> <div id="vector-toc-pinned-container" class="vector-pinned-container"> <div id="vector-toc" class="vector-toc vector-pinnable-element"> <div class="vector-pinnable-header vector-toc-pinnable-header vector-pinnable-header-pinned" data-feature-name="toc-pinned" data-pinnable-element-id="vector-toc" > <h2 class="vector-pinnable-header-label">Contents</h2> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-toc.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-toc.unpin">hide</button> </div> <ul class="vector-toc-contents" id="mw-panel-toc-list"> <li id="toc-mw-content-text" class="vector-toc-list-item vector-toc-level-1"> <a href="#" class="vector-toc-link"> <div class="vector-toc-text">(Top)</div> </a> </li> <li id="toc-Medical_uses" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Medical_uses"> <div class="vector-toc-text"> <span class="vector-toc-numb">1</span> <span>Medical uses</span> </div> </a> <ul id="toc-Medical_uses-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Adverse_effects" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Adverse_effects"> <div class="vector-toc-text"> <span class="vector-toc-numb">2</span> <span>Adverse effects</span> </div> </a> <ul id="toc-Adverse_effects-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Pharmacology" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Pharmacology"> <div class="vector-toc-text"> <span class="vector-toc-numb">3</span> <span>Pharmacology</span> </div> </a> <button aria-controls="toc-Pharmacology-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> <span class="vector-icon mw-ui-icon-wikimedia-expand"></span> <span>Toggle Pharmacology subsection</span> </button> <ul id="toc-Pharmacology-sublist" class="vector-toc-list"> <li id="toc-Mechanism_of_action" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Mechanism_of_action"> <div class="vector-toc-text"> <span class="vector-toc-numb">3.1</span> <span>Mechanism of action</span> </div> </a> <ul id="toc-Mechanism_of_action-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> <li id="toc-History" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#History"> <div class="vector-toc-text"> <span class="vector-toc-numb">4</span> <span>History</span> </div> </a> <ul id="toc-History-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-Society_and_culture" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Society_and_culture"> <div class="vector-toc-text"> <span class="vector-toc-numb">5</span> <span>Society and culture</span> </div> </a> <button aria-controls="toc-Society_and_culture-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> <span class="vector-icon mw-ui-icon-wikimedia-expand"></span> <span>Toggle Society and culture subsection</span> </button> <ul id="toc-Society_and_culture-sublist" class="vector-toc-list"> <li id="toc-Economics" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Economics"> <div class="vector-toc-text"> <span class="vector-toc-numb">5.1</span> <span>Economics</span> </div> </a> <ul id="toc-Economics-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> <li id="toc-Research" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#Research"> <div class="vector-toc-text"> <span class="vector-toc-numb">6</span> <span>Research</span> </div> </a> <ul id="toc-Research-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-References" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#References"> <div class="vector-toc-text"> <span class="vector-toc-numb">7</span> <span>References</span> </div> </a> <ul id="toc-References-sublist" class="vector-toc-list"> </ul> </li> <li id="toc-External_links" class="vector-toc-list-item vector-toc-level-1 vector-toc-list-item-expanded"> <a class="vector-toc-link" href="#External_links"> <div class="vector-toc-text"> <span class="vector-toc-numb">8</span> <span>External links</span> </div> </a> <button aria-controls="toc-External_links-sublist" class="cdx-button cdx-button--weight-quiet cdx-button--icon-only vector-toc-toggle"> <span class="vector-icon mw-ui-icon-wikimedia-expand"></span> <span>Toggle External links subsection</span> </button> <ul id="toc-External_links-sublist" class="vector-toc-list"> <li id="toc-Clinical_trials" class="vector-toc-list-item vector-toc-level-2"> <a class="vector-toc-link" href="#Clinical_trials"> <div class="vector-toc-text"> <span class="vector-toc-numb">8.1</span> <span>Clinical trials</span> </div> </a> <ul id="toc-Clinical_trials-sublist" class="vector-toc-list"> </ul> </li> </ul> </li> </ul> </div> </div> </nav> </div> </div> <div class="mw-content-container"> <main id="content" class="mw-body"> <header class="mw-body-header vector-page-titlebar"> <nav aria-label="Contents" class="vector-toc-landmark"> <div id="vector-page-titlebar-toc" class="vector-dropdown vector-page-titlebar-toc vector-button-flush-left" > <input type="checkbox" id="vector-page-titlebar-toc-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-titlebar-toc" class="vector-dropdown-checkbox " aria-label="Toggle the table of contents" > <label id="vector-page-titlebar-toc-label" for="vector-page-titlebar-toc-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--icon-only " aria-hidden="true" ><span class="vector-icon mw-ui-icon-listBullet mw-ui-icon-wikimedia-listBullet"></span> <span class="vector-dropdown-label-text">Toggle the table of contents</span> </label> <div class="vector-dropdown-content"> <div id="vector-page-titlebar-toc-unpinned-container" class="vector-unpinned-container"> </div> </div> </div> </nav> <h1 id="firstHeading" class="firstHeading mw-first-heading"><span class="mw-page-title-main">Atezolizumab</span></h1> <div id="p-lang-btn" class="vector-dropdown mw-portlet mw-portlet-lang" > <input type="checkbox" id="p-lang-btn-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-p-lang-btn" class="vector-dropdown-checkbox mw-interlanguage-selector" aria-label="Go to an article in another language. Available in 15 languages" > <label id="p-lang-btn-label" for="p-lang-btn-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet cdx-button--action-progressive mw-portlet-lang-heading-15" aria-hidden="true" ><span class="vector-icon mw-ui-icon-language-progressive mw-ui-icon-wikimedia-language-progressive"></span> <span class="vector-dropdown-label-text">15 languages</span> </label> <div class="vector-dropdown-content"> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li class="interlanguage-link interwiki-ar mw-list-item"><a href="https://ar.wikipedia.org/wiki/%D8%A3%D8%AA%D9%8A%D8%B2%D9%88%D9%84%D9%8A%D8%B2%D9%88%D9%85%D8%A7%D8%A8" title="أتيزوليزوماب – Arabic" lang="ar" hreflang="ar" data-title="أتيزوليزوماب" data-language-autonym="العربية" data-language-local-name="Arabic" class="interlanguage-link-target"><span>العربية</span></a></li><li class="interlanguage-link interwiki-de mw-list-item"><a href="https://de.wikipedia.org/wiki/Atezolizumab" title="Atezolizumab – German" lang="de" hreflang="de" data-title="Atezolizumab" data-language-autonym="Deutsch" data-language-local-name="German" class="interlanguage-link-target"><span>Deutsch</span></a></li><li class="interlanguage-link interwiki-es mw-list-item"><a href="https://es.wikipedia.org/wiki/Atezolizumab" title="Atezolizumab – Spanish" lang="es" hreflang="es" data-title="Atezolizumab" data-language-autonym="Español" data-language-local-name="Spanish" class="interlanguage-link-target"><span>Español</span></a></li><li class="interlanguage-link interwiki-fa mw-list-item"><a href="https://fa.wikipedia.org/wiki/%D8%A2%D8%AA%D8%B2%D9%88%D9%84%DB%8C%D8%B2%D9%88%D9%85%D8%A8" title="آتزولیزومب – Persian" lang="fa" hreflang="fa" data-title="آتزولیزومب" data-language-autonym="فارسی" data-language-local-name="Persian" class="interlanguage-link-target"><span>فارسی</span></a></li><li class="interlanguage-link interwiki-fr mw-list-item"><a href="https://fr.wikipedia.org/wiki/At%C3%A9zolizumab" title="Atézolizumab – French" lang="fr" hreflang="fr" data-title="Atézolizumab" data-language-autonym="Français" data-language-local-name="French" class="interlanguage-link-target"><span>Français</span></a></li><li class="interlanguage-link interwiki-it mw-list-item"><a href="https://it.wikipedia.org/wiki/Atezolizumab" title="Atezolizumab – Italian" lang="it" hreflang="it" data-title="Atezolizumab" data-language-autonym="Italiano" data-language-local-name="Italian" class="interlanguage-link-target"><span>Italiano</span></a></li><li class="interlanguage-link interwiki-ja mw-list-item"><a href="https://ja.wikipedia.org/wiki/%E3%82%A2%E3%83%86%E3%82%BE%E3%83%AA%E3%82%BA%E3%83%9E%E3%83%96" title="アテゾリズマブ – Japanese" lang="ja" hreflang="ja" data-title="アテゾリズマブ" data-language-autonym="日本語" data-language-local-name="Japanese" class="interlanguage-link-target"><span>日本語</span></a></li><li class="interlanguage-link interwiki-or mw-list-item"><a href="https://or.wikipedia.org/wiki/%E0%AC%86%E0%AC%9F%E0%AD%87%E0%AC%9C%E0%AD%8B%E0%AC%B2%E0%AC%BF%E0%AC%9C%E0%AD%81%E0%AC%AE%E0%AC%BE%E0%AC%AC" title="ଆଟେଜୋଲିଜୁମାବ – Odia" lang="or" hreflang="or" data-title="ଆଟେଜୋଲିଜୁମାବ" data-language-autonym="ଓଡ଼ିଆ" data-language-local-name="Odia" class="interlanguage-link-target"><span>ଓଡ଼ିଆ</span></a></li><li class="interlanguage-link interwiki-pl mw-list-item"><a href="https://pl.wikipedia.org/wiki/Atezolizumab" title="Atezolizumab – Polish" lang="pl" hreflang="pl" data-title="Atezolizumab" data-language-autonym="Polski" data-language-local-name="Polish" class="interlanguage-link-target"><span>Polski</span></a></li><li class="interlanguage-link interwiki-pt mw-list-item"><a href="https://pt.wikipedia.org/wiki/Atezolizumabe" title="Atezolizumabe – Portuguese" lang="pt" hreflang="pt" data-title="Atezolizumabe" data-language-autonym="Português" data-language-local-name="Portuguese" class="interlanguage-link-target"><span>Português</span></a></li><li class="interlanguage-link interwiki-ru mw-list-item"><a href="https://ru.wikipedia.org/wiki/%D0%90%D1%82%D0%B5%D0%B7%D0%BE%D0%BB%D0%B8%D0%B7%D1%83%D0%BC%D0%B0%D0%B1" title="Атезолизумаб – Russian" lang="ru" hreflang="ru" data-title="Атезолизумаб" data-language-autonym="Русский" data-language-local-name="Russian" class="interlanguage-link-target"><span>Русский</span></a></li><li class="interlanguage-link interwiki-sl mw-list-item"><a href="https://sl.wikipedia.org/wiki/Atezolizumab" title="Atezolizumab – Slovenian" lang="sl" hreflang="sl" data-title="Atezolizumab" data-language-autonym="Slovenščina" data-language-local-name="Slovenian" class="interlanguage-link-target"><span>Slovenščina</span></a></li><li class="interlanguage-link interwiki-tr mw-list-item"><a href="https://tr.wikipedia.org/wiki/Atezolizumab" title="Atezolizumab – Turkish" lang="tr" hreflang="tr" data-title="Atezolizumab" data-language-autonym="Türkçe" data-language-local-name="Turkish" class="interlanguage-link-target"><span>Türkçe</span></a></li><li class="interlanguage-link interwiki-uk mw-list-item"><a href="https://uk.wikipedia.org/wiki/%D0%90%D1%82%D0%B5%D0%B7%D0%BE%D0%BB%D1%96%D0%B7%D1%83%D0%BC%D0%B0%D0%B1" title="Атезолізумаб – Ukrainian" lang="uk" hreflang="uk" data-title="Атезолізумаб" data-language-autonym="Українська" data-language-local-name="Ukrainian" class="interlanguage-link-target"><span>Українська</span></a></li><li class="interlanguage-link interwiki-zh mw-list-item"><a href="https://zh.wikipedia.org/wiki/%E9%98%BF%E6%9B%BF%E5%88%A9%E7%8F%A0%E5%8D%95%E6%8A%97" title="阿替利珠单抗 – Chinese" lang="zh" hreflang="zh" data-title="阿替利珠单抗" data-language-autonym="中文" data-language-local-name="Chinese" class="interlanguage-link-target"><span>中文</span></a></li> </ul> <div class="after-portlet after-portlet-lang"><span class="wb-langlinks-edit wb-langlinks-link"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q20707748#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div> </div> </div> </div> </header> <div class="vector-page-toolbar"> <div class="vector-page-toolbar-container"> <div id="left-navigation"> <nav aria-label="Namespaces"> <div id="p-associated-pages" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-associated-pages" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-nstab-main" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Atezolizumab" title="View the content page [c]" accesskey="c"><span>Article</span></a></li><li id="ca-talk" class="vector-tab-noicon mw-list-item"><a href="/wiki/Talk:Atezolizumab" rel="discussion" title="Discuss improvements to the content page [t]" accesskey="t"><span>Talk</span></a></li> </ul> </div> </div> <div id="vector-variants-dropdown" class="vector-dropdown emptyPortlet" > <input type="checkbox" id="vector-variants-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-variants-dropdown" class="vector-dropdown-checkbox " aria-label="Change language variant" > <label id="vector-variants-dropdown-label" for="vector-variants-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true" ><span class="vector-dropdown-label-text">English</span> </label> <div class="vector-dropdown-content"> <div id="p-variants" class="vector-menu mw-portlet mw-portlet-variants emptyPortlet" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> </ul> </div> </div> </div> </div> </nav> </div> <div id="right-navigation" class="vector-collapsible"> <nav aria-label="Views"> <div id="p-views" class="vector-menu vector-menu-tabs mw-portlet mw-portlet-views" > <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-view" class="selected vector-tab-noicon mw-list-item"><a href="/wiki/Atezolizumab"><span>Read</span></a></li><li id="ca-edit" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Atezolizumab&action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-history" class="vector-tab-noicon mw-list-item"><a href="/w/index.php?title=Atezolizumab&action=history" title="Past revisions of this page [h]" accesskey="h"><span>View history</span></a></li> </ul> </div> </div> </nav> <nav class="vector-page-tools-landmark" aria-label="Page tools"> <div id="vector-page-tools-dropdown" class="vector-dropdown vector-page-tools-dropdown" > <input type="checkbox" id="vector-page-tools-dropdown-checkbox" role="button" aria-haspopup="true" data-event-name="ui.dropdown-vector-page-tools-dropdown" class="vector-dropdown-checkbox " aria-label="Tools" > <label id="vector-page-tools-dropdown-label" for="vector-page-tools-dropdown-checkbox" class="vector-dropdown-label cdx-button cdx-button--fake-button cdx-button--fake-button--enabled cdx-button--weight-quiet" aria-hidden="true" ><span class="vector-dropdown-label-text">Tools</span> </label> <div class="vector-dropdown-content"> <div id="vector-page-tools-unpinned-container" class="vector-unpinned-container"> <div id="vector-page-tools" class="vector-page-tools vector-pinnable-element"> <div class="vector-pinnable-header vector-page-tools-pinnable-header vector-pinnable-header-unpinned" data-feature-name="page-tools-pinned" data-pinnable-element-id="vector-page-tools" data-pinned-container-id="vector-page-tools-pinned-container" data-unpinned-container-id="vector-page-tools-unpinned-container" > <div class="vector-pinnable-header-label">Tools</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-page-tools.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-page-tools.unpin">hide</button> </div> <div id="p-cactions" class="vector-menu mw-portlet mw-portlet-cactions emptyPortlet vector-has-collapsible-items" title="More options" > <div class="vector-menu-heading"> Actions </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="ca-more-view" class="selected vector-more-collapsible-item mw-list-item"><a href="/wiki/Atezolizumab"><span>Read</span></a></li><li id="ca-more-edit" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Atezolizumab&action=edit" title="Edit this page [e]" accesskey="e"><span>Edit</span></a></li><li id="ca-more-history" class="vector-more-collapsible-item mw-list-item"><a href="/w/index.php?title=Atezolizumab&action=history"><span>View history</span></a></li> </ul> </div> </div> <div id="p-tb" class="vector-menu mw-portlet mw-portlet-tb" > <div class="vector-menu-heading"> General </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="t-whatlinkshere" class="mw-list-item"><a href="/wiki/Special:WhatLinksHere/Atezolizumab" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j"><span>What links here</span></a></li><li id="t-recentchangeslinked" class="mw-list-item"><a href="/wiki/Special:RecentChangesLinked/Atezolizumab" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k"><span>Related changes</span></a></li><li id="t-upload" class="mw-list-item"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u"><span>Upload file</span></a></li><li id="t-specialpages" class="mw-list-item"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q"><span>Special pages</span></a></li><li id="t-permalink" class="mw-list-item"><a href="/w/index.php?title=Atezolizumab&oldid=1248728230" title="Permanent link to this revision of this page"><span>Permanent link</span></a></li><li id="t-info" class="mw-list-item"><a href="/w/index.php?title=Atezolizumab&action=info" title="More information about this page"><span>Page information</span></a></li><li id="t-cite" class="mw-list-item"><a href="/w/index.php?title=Special:CiteThisPage&page=Atezolizumab&id=1248728230&wpFormIdentifier=titleform" title="Information on how to cite this page"><span>Cite this page</span></a></li><li id="t-urlshortener" class="mw-list-item"><a href="/w/index.php?title=Special:UrlShortener&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAtezolizumab"><span>Get shortened URL</span></a></li><li id="t-urlshortener-qrcode" class="mw-list-item"><a href="/w/index.php?title=Special:QrCode&url=https%3A%2F%2Fen.wikipedia.org%2Fwiki%2FAtezolizumab"><span>Download QR code</span></a></li> </ul> </div> </div> <div id="p-coll-print_export" class="vector-menu mw-portlet mw-portlet-coll-print_export" > <div class="vector-menu-heading"> Print/export </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li id="coll-download-as-rl" class="mw-list-item"><a href="/w/index.php?title=Special:DownloadAsPdf&page=Atezolizumab&action=show-download-screen" title="Download this page as a PDF file"><span>Download as PDF</span></a></li><li id="t-print" class="mw-list-item"><a href="/w/index.php?title=Atezolizumab&printable=yes" title="Printable version of this page [p]" accesskey="p"><span>Printable version</span></a></li> </ul> </div> </div> <div id="p-wikibase-otherprojects" class="vector-menu mw-portlet mw-portlet-wikibase-otherprojects" > <div class="vector-menu-heading"> In other projects </div> <div class="vector-menu-content"> <ul class="vector-menu-content-list"> <li class="wb-otherproject-link wb-otherproject-commons mw-list-item"><a href="https://commons.wikimedia.org/wiki/Category:Atezolizumab" hreflang="en"><span>Wikimedia Commons</span></a></li><li id="t-wikibase" class="wb-otherproject-link wb-otherproject-wikibase-dataitem mw-list-item"><a href="https://www.wikidata.org/wiki/Special:EntityPage/Q20707748" title="Structured data on this page hosted by Wikidata [g]" accesskey="g"><span>Wikidata item</span></a></li> </ul> </div> </div> </div> </div> </div> </div> </nav> </div> </div> </div> <div class="vector-column-end"> <div class="vector-sticky-pinned-container"> <nav class="vector-page-tools-landmark" aria-label="Page tools"> <div id="vector-page-tools-pinned-container" class="vector-pinned-container"> </div> </nav> <nav class="vector-appearance-landmark" aria-label="Appearance"> <div id="vector-appearance-pinned-container" class="vector-pinned-container"> <div id="vector-appearance" class="vector-appearance vector-pinnable-element"> <div class="vector-pinnable-header vector-appearance-pinnable-header vector-pinnable-header-pinned" data-feature-name="appearance-pinned" data-pinnable-element-id="vector-appearance" data-pinned-container-id="vector-appearance-pinned-container" data-unpinned-container-id="vector-appearance-unpinned-container" > <div class="vector-pinnable-header-label">Appearance</div> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-pin-button" data-event-name="pinnable-header.vector-appearance.pin">move to sidebar</button> <button class="vector-pinnable-header-toggle-button vector-pinnable-header-unpin-button" data-event-name="pinnable-header.vector-appearance.unpin">hide</button> </div> </div> </div> </nav> </div> </div> <div id="bodyContent" class="vector-body" aria-labelledby="firstHeading" data-mw-ve-target-container> <div class="vector-body-before-content"> <div class="mw-indicators"> </div> <div id="siteSub" class="noprint">From Wikipedia, the free encyclopedia</div> </div> <div id="contentSub"><div id="mw-content-subtitle"></div></div> <div id="mw-content-text" class="mw-body-content"><div class="mw-content-ltr mw-parser-output" lang="en" dir="ltr"><div class="shortdescription nomobile noexcerpt noprint searchaux" style="display:none">Monoclonal anti-PD-L1 antibody</div> <p class="mw-empty-elt"> </p> <style data-mw-deduplicate="TemplateStyles:r1257001546">.mw-parser-output .infobox-subbox{padding:0;border:none;margin:-3px;width:auto;min-width:100%;font-size:100%;clear:none;float:none;background-color:transparent}.mw-parser-output .infobox-3cols-child{margin:auto}.mw-parser-output .infobox .navbar{font-size:100%}@media screen{html.skin-theme-clientpref-night .mw-parser-output .infobox-full-data:not(.notheme)>div:not(.notheme)[style]{background:#1f1f23!important;color:#f8f9fa}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .infobox-full-data:not(.notheme) div:not(.notheme){background:#1f1f23!important;color:#f8f9fa}}@media(min-width:640px){body.skin--responsive .mw-parser-output .infobox-table{display:table!important}body.skin--responsive .mw-parser-output .infobox-table>caption{display:table-caption!important}body.skin--responsive .mw-parser-output .infobox-table>tbody{display:table-row-group}body.skin--responsive .mw-parser-output .infobox-table tr{display:table-row!important}body.skin--responsive .mw-parser-output .infobox-table th,body.skin--responsive .mw-parser-output .infobox-table td{padding-left:inherit;padding-right:inherit}}</style><table class="infobox" style="border-spacing:2px;"><caption class="infobox-title"><span title="International nonproprietary name (INN): Atezolizumab">Atezolizumab</span></caption><tbody><tr><td colspan="2" class="infobox-image notheme" style="background-color: #f8f9fa;"><span class="mw-default-size" typeof="mw:File/Frameless"><a href="/wiki/File:Atezolizumab_PD-L1_5X8L.png" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Atezolizumab_PD-L1_5X8L.png/220px-Atezolizumab_PD-L1_5X8L.png" decoding="async" width="220" height="220" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Atezolizumab_PD-L1_5X8L.png/330px-Atezolizumab_PD-L1_5X8L.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e6/Atezolizumab_PD-L1_5X8L.png/440px-Atezolizumab_PD-L1_5X8L.png 2x" data-file-width="2048" data-file-height="2048" /></a></span><div class="infobox-caption"><a href="/wiki/Fragment_antigen-binding" class="mw-redirect" title="Fragment antigen-binding">Antigen-binding fragment</a> of atezolizumab (blue) in complex with PD-L1 (pink).<span class="plainlinks"><a href="/wiki/Protein_Data_Bank" title="Protein Data Bank">PDB</a>: <a rel="nofollow" class="external text" href="https://www.rcsb.org/structure/5X8L">5X8L</a></span>.</div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd"><a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">Monoclonal antibody</a></th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/File:Engineered_monoclonal_antibodies.svg" title="File:Engineered monoclonal antibodies.svg">Type</a></th><td class="infobox-data">Whole antibody</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Monoclonal_antibody#Production" title="Monoclonal antibody">Source</a></th><td class="infobox-data"><a href="/wiki/Humanized" class="mw-redirect" title="Humanized">Humanized</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Antigen" title="Antigen">Target</a></th><td class="infobox-data"><a href="/wiki/PD-L1" title="PD-L1">PD-L1</a></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Clinical data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_nomenclature#Trade_names" title="Drug nomenclature">Trade names</a></th><td class="infobox-data">Tecentriq, Tecentriq SC</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;">Other names</th><td class="infobox-data">MPDL3280A, RG7446</td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/American_Society_of_Health-System_Pharmacists" title="American Society of Health-System Pharmacists">AHFS</a>/<a href="/wiki/Drugs.com" title="Drugs.com">Drugs.com</a></th><td class="infobox-data"><span title="www.drugs.com"><a rel="nofollow" class="external text" href="https://www.drugs.com/monograph/atezolizumab.html">Monograph</a></span></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/MedlinePlus" title="MedlinePlus">MedlinePlus</a></th><td class="infobox-data"><span title="medlineplus.gov"><a rel="nofollow" class="external text" href="https://medlineplus.gov/druginfo/meds/a616035.html">a616035</a></span></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">License data</a></th><td class="infobox-data"><style data-mw-deduplicate="TemplateStyles:r1126788409">.mw-parser-output .plainlist ol,.mw-parser-output .plainlist ul{line-height:inherit;list-style:none;margin:0;padding:0}.mw-parser-output .plainlist ol li,.mw-parser-output .plainlist ul li{margin-bottom:0}</style><div class="plainlist"> <ul><li><small><abbr class="country-name" title="United States">US</abbr></small> <a href="/wiki/DailyMed" title="DailyMed">DailyMed</a>: <span title="dailymed.nlm.nih.gov"><a rel="nofollow" class="external text" href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Atezolizumab">Atezolizumab</a></span></li></ul></div> </td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy<br />category</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"> <ul><li><small><abbr class="country-name" title="Australia">AU</abbr>:</small> D<sup id="cite_ref-Tecentriq_PI_1-0" class="reference"><a href="#cite_note-Tecentriq_PI-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup></li> <li class="mw-empty-elt"></li></ul> </div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes of<br />administration</a></th><td class="infobox-data"><a href="/wiki/Intravenous_therapy" title="Intravenous therapy">Intravenous infusion</a>, <a href="/wiki/Subcutaneous_administration" title="Subcutaneous administration">subcutaneous</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Drug_class" title="Drug class">Drug class</a></th><td class="infobox-data"><a href="/wiki/Antineoplastic_agent" class="mw-redirect" title="Antineoplastic agent">Antineoplastic agent</a></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><a href="/wiki/ATC_code_L01" title="ATC code L01">L01FF05</a> (<span title="www.whocc.no"><a rel="nofollow" class="external text" href="https://www.whocc.no/atc_ddd_index/?code=L01FF05">WHO</a></span>) </li></ul></div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Legal status</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"> <ul><li><small><abbr class="country-name" title="Australia">AU</abbr>:</small> <a href="/wiki/Standard_for_the_Uniform_Scheduling_of_Medicines_and_Poisons#Schedule_4" title="Standard for the Uniform Scheduling of Medicines and Poisons">S4</a> (Prescription only)<sup id="cite_ref-Tecentriq_PI_1-1" class="reference"><a href="#cite_note-Tecentriq_PI-1"><span class="cite-bracket">[</span>1<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-2" class="reference"><a href="#cite_note-2"><span class="cite-bracket">[</span>2<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-3" class="reference"><a href="#cite_note-3"><span class="cite-bracket">[</span>3<span class="cite-bracket">]</span></a></sup></li> <li><small><abbr class="country-name" title="Canada">CA</abbr></small>: <a href="/wiki/Prescription_drug" title="Prescription drug"> ℞-only</a><sup id="cite_ref-4" class="reference"><a href="#cite_note-4"><span class="cite-bracket">[</span>4<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-5" class="reference"><a href="#cite_note-5"><span class="cite-bracket">[</span>5<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-6" class="reference"><a href="#cite_note-6"><span class="cite-bracket">[</span>6<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-7" class="reference"><a href="#cite_note-7"><span class="cite-bracket">[</span>7<span class="cite-bracket">]</span></a></sup></li> <li><small><abbr class="country-name" title="United Kingdom">UK</abbr>:</small> <a href="/wiki/Prescription_drug" title="Prescription drug">POM</a> (Prescription only)<sup id="cite_ref-8" class="reference"><a href="#cite_note-8"><span class="cite-bracket">[</span>8<span class="cite-bracket">]</span></a></sup></li> <li><small><abbr class="country-name" title="United States">US</abbr>:</small> <a href="/wiki/Prescription_drug" title="Prescription drug">℞-only</a><sup id="cite_ref-Tecentriq_FDA_label_9-0" class="reference"><a href="#cite_note-Tecentriq_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup></li> <li><small><abbr class="country-name" title="European Union">EU</abbr>:</small> Rx-only<sup id="cite_ref-Tecentriq_EPAR_10-0" class="reference"><a href="#cite_note-Tecentriq_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup></li></ul></div> </td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Identifiers</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/CAS_Registry_Number" title="CAS Registry Number">CAS Number</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="commonchemistry.cas.org"><a rel="nofollow" class="external text" href="https://commonchemistry.cas.org/detail?cas_rn=1380723-44-3">1380723-44-3</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="www.drugbank.ca"><a rel="nofollow" class="external text" href="https://www.drugbank.ca/drugs/DB11595">DB11595</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li>none</li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Unique_Ingredient_Identifier" title="Unique Ingredient Identifier">UNII</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="precision.fda.gov"><a rel="nofollow" class="external text" href="https://precision.fda.gov/uniisearch/srs/unii/52CMI0WC3Y">52CMI0WC3Y</a></span></li></ul></div></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/KEGG" title="KEGG">KEGG</a></th><td class="infobox-data"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1126788409"><div class="plainlist"><ul><li><span title="www.kegg.jp"><a rel="nofollow" class="external text" href="https://www.kegg.jp/entry/D10773">D10773</a></span></li></ul></div></td></tr><tr><th colspan="2" class="infobox-header" style="background:#ddd">Chemical and physical data</th></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></th><td class="infobox-data"><span title="Carbon">C</span><sub>6446</sub><span title="Hydrogen">H</span><sub>9902</sub><span title="Nitrogen">N</span><sub>1706</sub><span title="Oxygen">O</span><sub>1998</sub><span title="Sulfur">S</span><sub>42</sub></td></tr><tr><th scope="row" class="infobox-label" style="line-height:1.2em;"><a href="/wiki/Molar_mass" title="Molar mass">Molar mass</a></th><td class="infobox-data"><span class="nowrap"><span data-sort-value="7005144612590000000♠"></span>144<span style="margin-left:.25em;">612</span>.59</span> g·mol<sup>−1</sup></td></tr></tbody></table> <p><b>Atezolizumab</b>, sold under the brand name <b>Tecentriq</b> among others, is a <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> medication used to treat <a href="/wiki/Urothelial_carcinoma" class="mw-redirect" title="Urothelial carcinoma">urothelial carcinoma</a>, <a href="/wiki/Non-small_cell_lung_cancer" class="mw-redirect" title="Non-small cell lung cancer">non-small cell lung cancer</a> (NSCLC), <a href="/wiki/Small_cell_lung_cancer" class="mw-redirect" title="Small cell lung cancer">small cell lung cancer</a> (SCLC), <a href="/wiki/Hepatocellular_carcinoma" title="Hepatocellular carcinoma">hepatocellular carcinoma</a> and <a href="/wiki/Alveolar_soft_part_sarcoma" title="Alveolar soft part sarcoma">alveolar soft part sarcoma</a>,<sup id="cite_ref-Tecentriq_FDA_label_9-1" class="reference"><a href="#cite_note-Tecentriq_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-11" class="reference"><a href="#cite_note-11"><span class="cite-bracket">[</span>11<span class="cite-bracket">]</span></a></sup> but discontinued for use in <a href="/wiki/Triple-negative_breast_cancer" title="Triple-negative breast cancer">triple-negative breast cancer</a> (TNBC).<sup id="cite_ref-Nature_12-0" class="reference"><a href="#cite_note-Nature-12"><span class="cite-bracket">[</span>12<span class="cite-bracket">]</span></a></sup> It is a fully <a href="/wiki/Humanized_antibody" title="Humanized antibody">humanized</a>, engineered <a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">monoclonal antibody</a> of <a href="/wiki/Immunoglobulin_G" title="Immunoglobulin G">IgG1</a> <a href="/wiki/Isotype_(immunology)" title="Isotype (immunology)">isotype</a> against the protein <a href="/wiki/Programmed_cell_death-ligand_1" class="mw-redirect" title="Programmed cell death-ligand 1">programmed cell death-ligand 1</a> (PD-L1).<sup id="cite_ref-GT2015_13-0" class="reference"><a href="#cite_note-GT2015-13"><span class="cite-bracket">[</span>13<span class="cite-bracket">]</span></a></sup> </p><p>The most common side effects when used on its own include tiredness, reduced appetite, nausea, vomiting, cough, difficulty breathing, diarrhea, rash, fever, pain in the back, joints, muscles and bones, weakness, itching and <a href="/wiki/Urinary_tract_infection" title="Urinary tract infection">urinary tract infection</a>.<sup id="cite_ref-Tecentriq_EPAR_10-1" class="reference"><a href="#cite_note-Tecentriq_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup> The most common side effects when used with other cancer medicines include <a href="/wiki/Peripheral_neuropathy" title="Peripheral neuropathy">peripheral neuropathy</a> (nerve damage in the hands and feet), nausea, <a href="/wiki/Anemia" title="Anemia">anemia</a> (low red blood cell counts), <a href="/wiki/Neutropenia" title="Neutropenia">neutropenia</a> (low white blood cell counts), <a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">thrombocytopenia</a> (low platelet counts), rash, tiredness, constipation, reduced appetite, diarrhea, and cough.<sup id="cite_ref-Tecentriq_EPAR_10-2" class="reference"><a href="#cite_note-Tecentriq_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup> </p><p>Atezolizumab was the first PD-L1 inhibitor approved by the U.S. for bladder cancer. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA).<sup id="cite_ref-FDA-BC-2016_14-0" class="reference"><a href="#cite_note-FDA-BC-2016-14"><span class="cite-bracket">[</span>14<span class="cite-bracket">]</span></a></sup> </p><p>In the European Union, atezolizumab is the first PD-(L)1 cancer immunotherapy for subcutaneous injection.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span class="cite-bracket">[</span>15<span class="cite-bracket">]</span></a></sup> </p> <meta property="mw:PageProp/toc" /> <div class="mw-heading mw-heading2"><h2 id="Medical_uses">Medical uses</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=1" title="Edit section: Medical uses"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>In the European Union, atezolizumab is <a href="/wiki/Indicated" class="mw-redirect" title="Indicated">indicated</a> for the treatment of urothelial carcinoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, urothelial carcinoma, and triple-negative breast cancer.<sup id="cite_ref-Tecentriq_EPAR_10-3" class="reference"><a href="#cite_note-Tecentriq_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup> It is no longer indicated for triple-negative breast cancer.<sup id="cite_ref-Nature_12-1" class="reference"><a href="#cite_note-Nature-12"><span class="cite-bracket">[</span>12<span class="cite-bracket">]</span></a></sup> </p><p>In the United States, atezolizumab is indicated for the treatment of non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma.<sup id="cite_ref-Tecentriq_FDA_label_9-2" class="reference"><a href="#cite_note-Tecentriq_FDA_label-9"><span class="cite-bracket">[</span>9<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-16" class="reference"><a href="#cite_note-16"><span class="cite-bracket">[</span>16<span class="cite-bracket">]</span></a></sup> Its indication for urothelial carcinoma was withdrawn in November 2022.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17"><span class="cite-bracket">[</span>17<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Adverse_effects">Adverse effects</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=2" title="Edit section: Adverse effects"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>The most common adverse effects in studies were <a href="/wiki/Fatigue_(medical)" class="mw-redirect" title="Fatigue (medical)">fatigue</a>, decreased appetite, <a href="/wiki/Nausea" title="Nausea">nausea</a>, and <a href="/wiki/Infection" title="Infection">infections</a>. Urinary tract infection was the most common severe adverse effect.<sup id="cite_ref-18" class="reference"><a href="#cite_note-18"><span class="cite-bracket">[</span>18<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Pharmacology">Pharmacology</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=3" title="Edit section: Pharmacology"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <div class="mw-heading mw-heading3"><h3 id="Mechanism_of_action">Mechanism of action</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=4" title="Edit section: Mechanism of action"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <figure class="mw-default-size" typeof="mw:File/Thumb"><a href="/wiki/File:Immunotherapy_%2B_Durvalumab_%2B_Pembrolizumab_%2B_Ipilimumab_%2B_Atezolizumab_mechanism_of_action.jpg" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/2/24/Immunotherapy_%2B_Durvalumab_%2B_Pembrolizumab_%2B_Ipilimumab_%2B_Atezolizumab_mechanism_of_action.jpg/220px-Immunotherapy_%2B_Durvalumab_%2B_Pembrolizumab_%2B_Ipilimumab_%2B_Atezolizumab_mechanism_of_action.jpg" decoding="async" width="220" height="122" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/2/24/Immunotherapy_%2B_Durvalumab_%2B_Pembrolizumab_%2B_Ipilimumab_%2B_Atezolizumab_mechanism_of_action.jpg/330px-Immunotherapy_%2B_Durvalumab_%2B_Pembrolizumab_%2B_Ipilimumab_%2B_Atezolizumab_mechanism_of_action.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/2/24/Immunotherapy_%2B_Durvalumab_%2B_Pembrolizumab_%2B_Ipilimumab_%2B_Atezolizumab_mechanism_of_action.jpg/440px-Immunotherapy_%2B_Durvalumab_%2B_Pembrolizumab_%2B_Ipilimumab_%2B_Atezolizumab_mechanism_of_action.jpg 2x" data-file-width="1694" data-file-height="939" /></a><figcaption>Non-small cell lung cancer (NSCLC) cells expressing programmed death-ligand 1 (PD-L1) could interact with programmed death receptor 1 (PD-1) expressed on the surface of T cells, and result in decreased tumor cell kill by the immune system. Atezolizumab is an anti PD-L1 monoclonal antibody. Nivolumab and pembrolizumab are anti PD-1 monoclonal antibodies. Ipilimumab is a monoclonal antibody that targets cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on the surface of T cells. Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) in the circulation and functions as an angiogenesis inhibitor. Source: First line Immunotherapy for Non-Small Cell Lung Cancer, Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals (Basel). 2020 <a rel="nofollow" class="external free" href="https://doi.org/10.3390/ph13110373">https://doi.org/10.3390/ph13110373</a><sup id="cite_ref-:1_19-0" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup></figcaption></figure> <p>Atezolizumab blocks the interaction of PD-L1 with <a href="/wiki/Programmed_cell_death_protein_1" title="Programmed cell death protein 1">programmed cell death protein 1</a> (PD-1) and <a href="/wiki/CD80" title="CD80">CD80</a> receptors (B7-1Rs).<sup id="cite_ref-:0_20-0" class="reference"><a href="#cite_note-:0-20"><span class="cite-bracket">[</span>20<span class="cite-bracket">]</span></a></sup> PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (<a href="/wiki/Cytotoxic_T_cell" title="Cytotoxic T cell">cytotoxic T-cells</a> in particular) that might otherwise recognize and attack the cancer.<sup id="cite_ref-:0_20-1" class="reference"><a href="#cite_note-:0-20"><span class="cite-bracket">[</span>20<span class="cite-bracket">]</span></a></sup> Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "<a href="/wiki/Immune_checkpoint" title="Immune checkpoint">immune checkpoint</a> inhibition."<sup id="cite_ref-:0_20-2" class="reference"><a href="#cite_note-:0-20"><span class="cite-bracket">[</span>20<span class="cite-bracket">]</span></a></sup> </p><p>For some cancers (notably bladder) the probability of benefit is related to PD-L1 expression, but most cancers with PD-L1 expression still do not respond, and many (about 15%) without PD-L1 expression do respond.<sup id="cite_ref-:0_20-3" class="reference"><a href="#cite_note-:0-20"><span class="cite-bracket">[</span>20<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="History">History</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=5" title="Edit section: History"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>In 2015, it was in <a href="/wiki/Clinical_trial" title="Clinical trial">clinical trials</a> as an <a href="/wiki/Cancer_immunotherapy" title="Cancer immunotherapy">immunotherapy</a> for several types of <a href="/wiki/Neoplasm" title="Neoplasm">solid tumors</a>.<sup id="cite_ref-GT2015_13-1" class="reference"><a href="#cite_note-GT2015-13"><span class="cite-bracket">[</span>13<span class="cite-bracket">]</span></a></sup> It was under investigation by <a href="/wiki/Genentech" title="Genentech">Genentech</a>/<a href="/wiki/Hoffmann-La_Roche" class="mw-redirect" title="Hoffmann-La Roche">Roche</a>.<sup id="cite_ref-GT2015_13-2" class="reference"><a href="#cite_note-GT2015-13"><span class="cite-bracket">[</span>13<span class="cite-bracket">]</span></a></sup> </p><p>In April 2016, Roche announced that atezolizumab had been granted <a href="/wiki/Fast_track_(FDA)" title="Fast track (FDA)">fast track status</a> for lung cancer by the U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA).<sup id="cite_ref-21" class="reference"><a href="#cite_note-21"><span class="cite-bracket">[</span>21<span class="cite-bracket">]</span></a></sup> </p><p>In May 2016, the FDA granted <a href="/wiki/Accelerated_approval" class="mw-redirect" title="Accelerated approval">accelerated approval</a> to atezolizumab for locally advanced or metastatic <a href="/wiki/Urothelial_carcinoma" class="mw-redirect" title="Urothelial carcinoma">urothelial carcinoma</a> treatment after failure of cisplatin-based chemotherapy.<sup id="cite_ref-FDA-BC-2016_14-1" class="reference"><a href="#cite_note-FDA-BC-2016-14"><span class="cite-bracket">[</span>14<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-22" class="reference"><a href="#cite_note-22"><span class="cite-bracket">[</span>22<span class="cite-bracket">]</span></a></sup> The <a href="/wiki/Phases_of_clinical_research#Phase_IV" title="Phases of clinical research">confirmatory trial</a> (to convert the accelerated approval into a full approval) failed to achieve its <a href="/wiki/Primary_endpoint" class="mw-redirect" title="Primary endpoint">primary endpoint</a> of <a href="/wiki/Overall_survival" class="mw-redirect" title="Overall survival">overall survival</a>.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23"><span class="cite-bracket">[</span>23<span class="cite-bracket">]</span></a></sup> In 2018, FDA altered the use of atezolizumab as a first-line treatment for metastatic bladder cancer in people who can't receive cisplatin-based chemotherapy and have high levels of PD-L1.<sup id="cite_ref-24" class="reference"><a href="#cite_note-24"><span class="cite-bracket">[</span>24<span class="cite-bracket">]</span></a></sup> </p><p>In May 2016, atezolizumab was approved by the FDA for the treatment of people with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.<sup id="cite_ref-FDA_20160518_25-0" class="reference"><a href="#cite_note-FDA_20160518-25"><span class="cite-bracket">[</span>25<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-FDA-BC-2016_14-2" class="reference"><a href="#cite_note-FDA-BC-2016-14"><span class="cite-bracket">[</span>14<span class="cite-bracket">]</span></a></sup> In May 2017, atezolizumab failed a phase III trial for second line bladder cancer.<sup id="cite_ref-26" class="reference"><a href="#cite_note-26"><span class="cite-bracket">[</span>26<span class="cite-bracket">]</span></a></sup> </p><p>The safety and efficacy of atezolizumab were studied in people with urothelial carcinoma.<sup id="cite_ref-FDA-BC-2016_14-3" class="reference"><a href="#cite_note-FDA-BC-2016-14"><span class="cite-bracket">[</span>14<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-FDA_20160518_25-1" class="reference"><a href="#cite_note-FDA_20160518-25"><span class="cite-bracket">[</span>25<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-FDA_snapshot_27-0" class="reference"><a href="#cite_note-FDA_snapshot-27"><span class="cite-bracket">[</span>27<span class="cite-bracket">]</span></a></sup> Tumors temporarily shrank in a minority of participants, with people being more likely to benefit if the tumor expressed PD-L1.<sup id="cite_ref-FDA-BC-2016_14-4" class="reference"><a href="#cite_note-FDA-BC-2016-14"><span class="cite-bracket">[</span>14<span class="cite-bracket">]</span></a></sup> The trial was conducted in the United States, Canada, Spain, France, Great Britain, Germany, Italy and the Netherlands.<sup id="cite_ref-FDA_snapshot_27-1" class="reference"><a href="#cite_note-FDA_snapshot-27"><span class="cite-bracket">[</span>27<span class="cite-bracket">]</span></a></sup> </p><p>In October 2016, atezolizumab was approved by the FDA for the treatment of people with metastatic non-small cell lung cancer (NSCLC) whose disease progressed during or following platinum-containing chemotherapy.<sup id="cite_ref-FDA-10-18-2016_28-0" class="reference"><a href="#cite_note-FDA-10-18-2016-28"><span class="cite-bracket">[</span>28<span class="cite-bracket">]</span></a></sup> People with <a href="/wiki/Non-small-cell_lung_carcinoma#EGFR_mutations" class="mw-redirect" title="Non-small-cell lung carcinoma">EGFR or ALK genomic tumor aberrations</a> should have disease progression on FDA-approved therapy for these aberrations prior to receiving atezolizumab.<sup id="cite_ref-FDA-10-18-2016_28-1" class="reference"><a href="#cite_note-FDA-10-18-2016-28"><span class="cite-bracket">[</span>28<span class="cite-bracket">]</span></a></sup> </p><p>This approval was based on two international, randomized, open-label clinical trials (OAK and POPLAR) that demonstrated consistent results in efficacy and safety in a total of 1137 participants with NSCLC.<sup id="cite_ref-FDA-10-18-2016_28-2" class="reference"><a href="#cite_note-FDA-10-18-2016-28"><span class="cite-bracket">[</span>28<span class="cite-bracket">]</span></a></sup> Compared with docetaxel, treatment with atezolizumab in the intended participants population in the two trials resulted in a 4.2 and a 2.9 month improvement in overall survival (OS), respectively.<sup id="cite_ref-FDA-10-18-2016_28-3" class="reference"><a href="#cite_note-FDA-10-18-2016-28"><span class="cite-bracket">[</span>28<span class="cite-bracket">]</span></a></sup> </p><p>Atezolizumab was approved for medical use in the European Union in September 2017.<sup id="cite_ref-Tecentriq_EPAR_10-4" class="reference"><a href="#cite_note-Tecentriq_EPAR-10"><span class="cite-bracket">[</span>10<span class="cite-bracket">]</span></a></sup> </p><p>In May 2018, the use of atezolizumab in combination with <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a> (Avastin) and standard chemotherapy for some people with lung cancer was granted priority review.<sup id="cite_ref-29" class="reference"><a href="#cite_note-29"><span class="cite-bracket">[</span>29<span class="cite-bracket">]</span></a></sup> </p><p>In August 2018, the FDA updated the prescribing information for atezolizumab to require the use of an FDA-approved companion diagnostic test to determine PD-L1 levels in tumor tissue from people with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible.<sup id="cite_ref-30" class="reference"><a href="#cite_note-30"><span class="cite-bracket">[</span>30<span class="cite-bracket">]</span></a></sup> </p><p>In September 2018, it was announced that atezolizumab prolongs survival in extensive stage SCLC treatment, according to study results presented at the 19th World Conference on Lung Cancer (WCLC) in Toronto, Canada.<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Identifying_reliable_sources_(medicine)" title="Wikipedia:Identifying reliable sources (medicine)"><span title="Material near this tag needs references to reliable medical sources. (August 2020)">medical citation needed</span></a></i>]</sup> </p><p>In October 2018, a combined clinical trial of the drug with <a href="/wiki/Protein-bound_paclitaxel" title="Protein-bound paclitaxel">nab-paclitaxel</a> on people with advanced TNBC concluded.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31"><span class="cite-bracket">[</span>31<span class="cite-bracket">]</span></a></sup> </p><p>Atezolizumab, in combination with <a href="/wiki/Bevacizumab" title="Bevacizumab">bevacizumab</a>, <a href="/wiki/Paclitaxel" title="Paclitaxel">paclitaxel</a>, and <a href="/wiki/Carboplatin" title="Carboplatin">carboplatin</a>, was approved in the United States in December 2018, for the first-line treatment of people with metastatic non-squamous, non-small cell lung cancer (NSq NSCLC) with no EGFR or ALK genomic tumor aberrations.<sup id="cite_ref-FDA_PR_December_2016_32-0" class="reference"><a href="#cite_note-FDA_PR_December_2016-32"><span class="cite-bracket">[</span>32<span class="cite-bracket">]</span></a></sup> Approval was based on the IMpower150 trial (NCT02366143), an open-label, randomized (1:1:1), three-arm trial enrolling 1202 participants receiving first-line treatment for metastatic NSq NSCLC.<sup id="cite_ref-FDA_PR_December_2016_32-1" class="reference"><a href="#cite_note-FDA_PR_December_2016-32"><span class="cite-bracket">[</span>32<span class="cite-bracket">]</span></a></sup> </p><p>In March 2019, it was approved in the United States, in combination with paclitaxel protein-bound, for adults with unresectable locally advanced or metastatic TNBC whose tumors express PD-L1 (PD-L1 stained <a href="/wiki/Tumor-infiltrating_immune_cell" class="mw-redirect" title="Tumor-infiltrating immune cell">tumor-infiltrating immune cells</a> [IC] of any intensity covering ≥ 1% of the tumor area), as determined by an FDA-approved test.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33"><span class="cite-bracket">[</span>33<span class="cite-bracket">]</span></a></sup> The FDA also approved the VENTANA PD-L1 (SP142) Assay as a companion diagnostic device for selecting TNBC patients for atezolizumab.<sup id="cite_ref-FDA_PR_20190308_34-0" class="reference"><a href="#cite_note-FDA_PR_20190308-34"><span class="cite-bracket">[</span>34<span class="cite-bracket">]</span></a></sup> </p><p>Approval was based on IMpassion130 (NCT02425891), a multicenter, international, double-blinded, placebo-controlled, randomized trial that included 902 participants with unresectable locally advanced or metastatic TNBC who had not received prior chemotherapy for metastatic disease.<sup id="cite_ref-FDA_PR_20190308_34-1" class="reference"><a href="#cite_note-FDA_PR_20190308-34"><span class="cite-bracket">[</span>34<span class="cite-bracket">]</span></a></sup> Participants were randomized (1:1) to receive either atezolizumab (840 mg) or placebo intravenous infusions on days 1 and 15 of every 28-day cycle, plus paclitaxel protein-bound (100 mg/m2) administered via intravenous infusion on days 1, 8, and 15 of every 28-day cycle.<sup id="cite_ref-FDA_PR_20190308_34-2" class="reference"><a href="#cite_note-FDA_PR_20190308-34"><span class="cite-bracket">[</span>34<span class="cite-bracket">]</span></a></sup> </p><p>Also in March 2019, it was approved in the United States, in combination with carboplatin and <a href="/wiki/Etoposide" title="Etoposide">etoposide</a>, for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).<sup id="cite_ref-FDA_PR_20190319_35-0" class="reference"><a href="#cite_note-FDA_PR_20190319-35"><span class="cite-bracket">[</span>35<span class="cite-bracket">]</span></a></sup> </p><p>Approval was based on IMpower133 (NCT02763579), a randomized (1:1), multicenter, double-blind, placebo-controlled trial in 403 participants with ES-SCLC who received no prior chemotherapy for extensive stage disease and had ECOG performance status 0 or 1.<sup id="cite_ref-FDA_PR_20190319_35-1" class="reference"><a href="#cite_note-FDA_PR_20190319-35"><span class="cite-bracket">[</span>35<span class="cite-bracket">]</span></a></sup> </p><p>In December 2019, atezolizumab in combination with paclitaxel protein-bound and carboplatin was approved by the FDA for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations.<sup id="cite_ref-FDA_PR_20191203_36-0" class="reference"><a href="#cite_note-FDA_PR_20191203-36"><span class="cite-bracket">[</span>36<span class="cite-bracket">]</span></a></sup> </p><p>Efficacy was evaluated in IMpower130 (NCT02367781), a multicenter, randomized (2:1), open-label trial in participants with stage IV non-squamous NSCLC who had received no prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor, if appropriate.<sup id="cite_ref-FDA_PR_20191203_36-1" class="reference"><a href="#cite_note-FDA_PR_20191203-36"><span class="cite-bracket">[</span>36<span class="cite-bracket">]</span></a></sup> The trial randomized 724 participants (ITT) to either receive atezolizumab, paclitaxel protein-bound, and carboplatin, followed by single-agent atezolizumab, or to receive paclitaxel protein-bound and carboplatin, followed by maintenance pemetrexed at the investigator's discretion.<sup id="cite_ref-FDA_PR_20191203_36-2" class="reference"><a href="#cite_note-FDA_PR_20191203-36"><span class="cite-bracket">[</span>36<span class="cite-bracket">]</span></a></sup> </p><p>In May 2020, the atezolizumab was approved by the FDA for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK genomic tumor aberrations.<sup id="cite_ref-FDA_PR_20200518_37-0" class="reference"><a href="#cite_note-FDA_PR_20200518-37"><span class="cite-bracket">[</span>37<span class="cite-bracket">]</span></a></sup> </p><p>Efficacy was evaluated in IMpower110 (NCT02409342), a multicenter, international, randomized, open-label trial in participants with stage IV NSCLC whose tumors express PD-L1 (TC ≥ 1% or IC ≥ 1%), who had received no prior chemotherapy for metastatic disease.<sup id="cite_ref-FDA_PR_20200518_37-1" class="reference"><a href="#cite_note-FDA_PR_20200518-37"><span class="cite-bracket">[</span>37<span class="cite-bracket">]</span></a></sup> Participants were randomized (1:1) to receive atezolizumab 1200 mg every three weeks (until disease progression or unacceptable toxicity) or platinum-based chemotherapy.<sup id="cite_ref-FDA_PR_20200518_37-2" class="reference"><a href="#cite_note-FDA_PR_20200518-37"><span class="cite-bracket">[</span>37<span class="cite-bracket">]</span></a></sup> </p><p>Also in May 2020, atezolizumab in combination with bevacizumab was approved by the FDA for people with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.<sup id="cite_ref-FDA_PR_20200529_38-0" class="reference"><a href="#cite_note-FDA_PR_20200529-38"><span class="cite-bracket">[</span>38<span class="cite-bracket">]</span></a></sup> </p><p>Efficacy was investigated in IMbrave150 (NCT03434379), a multicenter, international, open-label, randomized trial in participants with locally advanced unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy.<sup id="cite_ref-FDA_PR_20200529_38-1" class="reference"><a href="#cite_note-FDA_PR_20200529-38"><span class="cite-bracket">[</span>38<span class="cite-bracket">]</span></a></sup> A total of 501 participants were randomized (2:1) to receive either atezolizumab 1200 mg as an intravenous infusion (IV) followed by bevacizumab 15 mg/kg IV on the same day, every 3 weeks, or sorafenib orally twice daily.<sup id="cite_ref-FDA_PR_20200529_38-2" class="reference"><a href="#cite_note-FDA_PR_20200529-38"><span class="cite-bracket">[</span>38<span class="cite-bracket">]</span></a></sup> </p><p>In July 2020, it was approved in the United States, in combination with <a href="/wiki/Cobimetinib" title="Cobimetinib">cobimetinib</a> and <a href="/wiki/Vemurafenib" title="Vemurafenib">vemurafenib</a>, for the treatment of people with BRAF V600 mutation-positive unresectable or metastatic melanoma.<sup id="cite_ref-FDA_PR_20200730_39-0" class="reference"><a href="#cite_note-FDA_PR_20200730-39"><span class="cite-bracket">[</span>39<span class="cite-bracket">]</span></a></sup> </p><p>Efficacy in combination with cobimetinib and vemurafenib was evaluated in a double-blind, randomized (1:1), placebo-controlled, multicenter trial (IMspire150, NCT02908672) in 514 participants.<sup id="cite_ref-FDA_PR_20200730_39-1" class="reference"><a href="#cite_note-FDA_PR_20200730-39"><span class="cite-bracket">[</span>39<span class="cite-bracket">]</span></a></sup> After a 28-day cycle of cobimetinib and vemurafenib, participants received atezolizumab 840 mg intravenous infusion every 2 weeks in combination with cobimetinib 60 mg orally once daily and vemurafenib 720 mg orally twice daily, or placebo in combination with cobimetinib 60 mg orally once daily (21 days on/7 days off) and vemurafenib 960 mg orally twice daily.<sup id="cite_ref-FDA_PR_20200730_39-2" class="reference"><a href="#cite_note-FDA_PR_20200730-39"><span class="cite-bracket">[</span>39<span class="cite-bracket">]</span></a></sup> </p> <figure class="mw-default-size" typeof="mw:File/Thumb"><a href="/wiki/File:Atezolizumab_for_treatment_of_non_small_cell_lung_cancer_in_the_first_line,_IMpower_110,_130_and_150_studies.jpg" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Atezolizumab_for_treatment_of_non_small_cell_lung_cancer_in_the_first_line%2C_IMpower_110%2C_130_and_150_studies.jpg/220px-Atezolizumab_for_treatment_of_non_small_cell_lung_cancer_in_the_first_line%2C_IMpower_110%2C_130_and_150_studies.jpg" decoding="async" width="220" height="418" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Atezolizumab_for_treatment_of_non_small_cell_lung_cancer_in_the_first_line%2C_IMpower_110%2C_130_and_150_studies.jpg/330px-Atezolizumab_for_treatment_of_non_small_cell_lung_cancer_in_the_first_line%2C_IMpower_110%2C_130_and_150_studies.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Atezolizumab_for_treatment_of_non_small_cell_lung_cancer_in_the_first_line%2C_IMpower_110%2C_130_and_150_studies.jpg/440px-Atezolizumab_for_treatment_of_non_small_cell_lung_cancer_in_the_first_line%2C_IMpower_110%2C_130_and_150_studies.jpg 2x" data-file-width="492" data-file-height="935" /></a><figcaption>Patients median survival with atezolizumab (Atezo) for treatment of non small cell lung cancer in the first line, IMpower 110 comparing Atezo to chemotherapy, IMpower 130 comparing Atezo+chemotherapy to chemotherapy, and IMpower150 comparing Atezo+chemotherapy+bevacizumab versus chemotherapy+bevacizumab. Adapted from: First line Immunotherapy for Non-Small Cell Lung Cancer. Nicola J. Nasser, Miguel Gorenberg, Abed Agbarya. Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. https://doi.org/10.3390/ph13110373</figcaption></figure> <p>IMpower110 randomized patients with stage IV NSCLC with PD-L1 expression ≥ 1% to atezolizumab single agent or to chemotherapy.<sup id="cite_ref-:1_19-1" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> The chemotherapy used was Cisplatin or Carboplatin, combined with gemcitabine for patient with squamous cell NSCLC, or pemetrexed for patients with nonsquamous disease.<sup id="cite_ref-:1_19-2" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> Atezolizumab was better tolerated than chemotherapy. In the subgroup of patients with EGFR and ALK wild-type tumors who had PD-L1 stained ≥ 50% of tumor cells (205 patients), the overall survival was 20.2 months with atezolizumab, and 13.1 months with chemotherapy.<sup id="cite_ref-:1_19-3" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> FDA approval is for patients with PD-L1 stained ≥ 50% of tumor cells, or PD-L1 stained tumor-infiltrating immune cells covering ≥ 10% of the tumor area, with no EGFR or ALK genomic tumor aberrations.<sup id="cite_ref-:1_19-4" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> </p><p>IMpower130 was an open-label, phase III trial that compared atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy, with chemotherapy alone as first-line treatment for metastatic non-squamous NSCLC.<sup id="cite_ref-:1_19-5" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> About half of the patients had PD-L1 negative tumors. Median overall survival was 18.6 months in the atezolizumab plus chemotherapy group and 13.9 months in the chemotherapy group; HR 0.79, p = 0.033.<sup id="cite_ref-:1_19-6" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> Subgroup analysis showed progression free survival benefit, and a trend toward overall survival benefit in all PD-L1 expression levels.<sup id="cite_ref-:1_19-7" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> </p><p>IMpower150 randomized patients with NSq NSCLC to treatment with chemotherapy plus bevacizumab, chemotherapy plus atezolizumab or chemotherapy plus bevacizumab and atezolizumab.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40"><span class="cite-bracket">[</span>40<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:1_19-8" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> The chemotherapy used was carboplatin and paclitaxel.<sup id="cite_ref-:1_19-9" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> Median overall survival was 19.8 and 14.9 months for patients treated with chemotherapy plus bevacizumab, with or without atezolizumab, respectively.<sup id="cite_ref-:1_19-10" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> Median OS with atezolizumab and chemotherapy alone was 19.5 months, raising question with regard to the added value of Bevacizumab to this combination for the general patients population.<sup id="cite_ref-:1_19-11" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> Importantly, patients with baseline liver metastases had an improved overall survival with atezolizumab, bevacizumab, and chemotherapy combination, compared to bevacizumab and chemotherapy alone, with a median OS of 13.3 and 9.4 months, respectively, HR 0.52.<sup id="cite_ref-:1_19-12" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> No improvement in overall survival was observed for patients with liver metastasis treated with chemotherapy and atezolizumab compared to patients treated with chemotherapy and bevacizumab.<sup id="cite_ref-:1_19-13" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> Recent report about safety and patient-reported outcomes of atezolizumab plus chemotherapy and bevacizumab shows that this drug combination seems tolerable and with manageable toxicities.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41"><span class="cite-bracket">[</span>41<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-:1_19-14" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> For patients with NSq NSCLC with baseline liver metastases, the combination of chemotherapy, atezolizumab and bevacizumab could be an option to consider in the first line.<sup id="cite_ref-:1_19-15" class="reference"><a href="#cite_note-:1-19"><span class="cite-bracket">[</span>19<span class="cite-bracket">]</span></a></sup> </p><p>In August 2023, Great Britain's Healthcare Products Regulatory Agency (MHRA) approved subcutaneous atezolizumab for all indications in which the intravenous formulation of the drug has been approved, including select types of lung, bladder, breast, and liver cancers. After receiving approval NHS England stated that hundreds of patients who were treated with the immunotherapy, are set to receive "under the skin" injections of atezolizumab, which will eventually lead to more time for cancer teams.<sup id="cite_ref-42" class="reference"><a href="#cite_note-42"><span class="cite-bracket">[</span>42<span class="cite-bracket">]</span></a></sup> </p><p>In January 2024, the European Commission granted marketing authorisation for Tecentriq® SC (atezolizumab), as the first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection in the European Union.<sup id="cite_ref-43" class="reference"><a href="#cite_note-43"><span class="cite-bracket">[</span>43<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Society_and_culture">Society and culture</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=6" title="Edit section: Society and culture"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <div class="mw-heading mw-heading3"><h3 id="Economics">Economics</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=7" title="Edit section: Economics"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>Atezolizumab treatment costs on average <span style="white-space: nowrap">US$13,200</span> per month in the United States, depending on the dosage schedule.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44"><span class="cite-bracket">[</span>44<span class="cite-bracket">]</span></a></sup> Despite updated data showing 30% more people with extensive stage <a href="/wiki/Small_cell_lung_cancer" class="mw-redirect" title="Small cell lung cancer">small cell lung cancer</a> have survived at 24 months, compared to those who received chemotherapy alone,<sup id="cite_ref-45" class="reference"><a href="#cite_note-45"><span class="cite-bracket">[</span>45<span class="cite-bracket">]</span></a></sup> Canadian regulators had rejected funding for atezolizumab to treat extensive stage small-cell lung cancer "as too costly" followed by United Kingdom also citing "drug's cost-effectiveness."<sup id="cite_ref-46" class="reference"><a href="#cite_note-46"><span class="cite-bracket">[</span>46<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-47" class="reference"><a href="#cite_note-47"><span class="cite-bracket">[</span>47<span class="cite-bracket">]</span></a></sup> However, U.K. reversed its previous decision and approved Tecentriq for extensive stage small cell lung cancer after price reconsideration on 27 May 2020.<sup id="cite_ref-48" class="reference"><a href="#cite_note-48"><span class="cite-bracket">[</span>48<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-49" class="reference"><a href="#cite_note-49"><span class="cite-bracket">[</span>49<span class="cite-bracket">]</span></a></sup> </p> <div class="mw-heading mw-heading2"><h2 id="Research">Research</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=8" title="Edit section: Research"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <p>As of 2016<sup class="plainlinks noexcerpt noprint asof-tag update" style="display:none;"><a class="external text" href="https://en.wikipedia.org/w/index.php?title=Atezolizumab&action=edit">[update]</a></sup>, it is in clinical trials for colorectal cancer, <a href="/wiki/Melanoma" title="Melanoma">melanoma</a>, <a href="/wiki/Breast_cancer" title="Breast cancer">breast cancer</a>, <a href="/wiki/Non-small-cell_lung_carcinoma" class="mw-redirect" title="Non-small-cell lung carcinoma">non-small-cell lung carcinoma</a>, <a href="/wiki/Bladder_cancer" title="Bladder cancer">bladder cancer</a>, <a href="/wiki/Renal_cell_carcinoma" title="Renal cell carcinoma">renal cell carcinoma</a>.<sup id="cite_ref-NCT_50-0" class="reference"><a href="#cite_note-NCT-50"><span class="cite-bracket">[</span>50<span class="cite-bracket">]</span></a></sup><sup id="cite_ref-51" class="reference"><a href="#cite_note-51"><span class="cite-bracket">[</span>51<span class="cite-bracket">]</span></a></sup><sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items" title="Wikipedia:Manual of Style/Dates and numbers"><span title="The date of the event predicted near this tag has passed. (March 2020)">needs update</span></a></i>]</sup> </p><p>Promising results have been observed for melanoma and non-small-cell lung cancer,<sup id="cite_ref-atezolizumab_in_the_treatment_of_metastatic_non-small-cell_lung_cancer_52-0" class="reference"><a href="#cite_note-atezolizumab_in_the_treatment_of_metastatic_non-small-cell_lung_cancer-52"><span class="cite-bracket">[</span>52<span class="cite-bracket">]</span></a></sup> and bladder cancer.<sup id="cite_ref-GT2015_13-3" class="reference"><a href="#cite_note-GT2015-13"><span class="cite-bracket">[</span>13<span class="cite-bracket">]</span></a></sup> </p><p>A phase I trial reported a 19% <a href="/wiki/Objective_response_rate" class="mw-redirect" title="Objective response rate">objective response rate</a> in metastatic <a href="/wiki/Triple-negative_breast_cancer" title="Triple-negative breast cancer">triple-negative breast cancer</a>.<sup id="cite_ref-53" class="reference"><a href="#cite_note-53"><span class="cite-bracket">[</span>53<span class="cite-bracket">]</span></a></sup> </p><p>As of 2019, atezolizumab is in trial for several types of cancer, such as <a href="/wiki/Pancreatic_cancer" title="Pancreatic cancer">pancreatic cancer</a>, <a href="/wiki/Gastric_cancer" class="mw-redirect" title="Gastric cancer">gastric cancer</a> and <a href="/wiki/Ovarian_Cancer" class="mw-redirect" title="Ovarian Cancer">ovarian Cancer</a>.<sup id="cite_ref-54" class="reference"><a href="#cite_note-54"><span class="cite-bracket">[</span>54<span class="cite-bracket">]</span></a></sup><sup class="noprint Inline-Template" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Manual_of_Style/Dates_and_numbers#Chronological_items" title="Wikipedia:Manual of Style/Dates and numbers"><span title="The date of the event predicted near this tag has passed. (March 2020)">needs update</span></a></i>]</sup> </p> <div class="mw-heading mw-heading2"><h2 id="References">References</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=9" title="Edit section: References"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <style data-mw-deduplicate="TemplateStyles:r1239543626">.mw-parser-output .reflist{margin-bottom:0.5em;list-style-type:decimal}@media screen{.mw-parser-output .reflist{font-size:90%}}.mw-parser-output .reflist .references{font-size:100%;margin-bottom:0;list-style-type:inherit}.mw-parser-output .reflist-columns-2{column-width:30em}.mw-parser-output .reflist-columns-3{column-width:25em}.mw-parser-output .reflist-columns{margin-top:0.3em}.mw-parser-output .reflist-columns ol{margin-top:0}.mw-parser-output .reflist-columns li{page-break-inside:avoid;break-inside:avoid-column}.mw-parser-output .reflist-upper-alpha{list-style-type:upper-alpha}.mw-parser-output .reflist-upper-roman{list-style-type:upper-roman}.mw-parser-output .reflist-lower-alpha{list-style-type:lower-alpha}.mw-parser-output .reflist-lower-greek{list-style-type:lower-greek}.mw-parser-output .reflist-lower-roman{list-style-type:lower-roman}</style><div class="reflist"> <div class="mw-references-wrap mw-references-columns"><ol class="references"> <li id="cite_note-Tecentriq_PI-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-Tecentriq_PI_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Tecentriq_PI_1-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><style data-mw-deduplicate="TemplateStyles:r1238218222">.mw-parser-output cite.citation{font-style:inherit;word-wrap:break-word}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .citation:target{background-color:rgba(0,127,255,0.133)}.mw-parser-output .id-lock-free.id-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/6/65/Lock-green.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-limited.id-lock-limited a,.mw-parser-output .id-lock-registration.id-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/d/d6/Lock-gray-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .id-lock-subscription.id-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/a/aa/Lock-red-alt-2.svg")right 0.1em center/9px no-repeat}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/4/4c/Wikisource-logo.svg")right 0.1em center/12px no-repeat}body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-free a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-limited a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-registration a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .id-lock-subscription a,body:not(.skin-timeless):not(.skin-minerva) .mw-parser-output .cs1-ws-icon a{background-size:contain;padding:0 1em 0 0}.mw-parser-output .cs1-code{color:inherit;background:inherit;border:none;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;color:var(--color-error,#d33)}.mw-parser-output .cs1-visible-error{color:var(--color-error,#d33)}.mw-parser-output .cs1-maint{display:none;color:#085;margin-left:0.3em}.mw-parser-output .cs1-kern-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right{padding-right:0.2em}.mw-parser-output .citation .mw-selflink{font-weight:inherit}@media screen{.mw-parser-output .cs1-format{font-size:95%}html.skin-theme-clientpref-night .mw-parser-output .cs1-maint{color:#18911f}}@media screen and (prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .cs1-maint{color:#18911f}}</style><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.guildlink.com.au/gc/ws/ro/pi.cfm?product=roptecen10717">"Tecentriq PI"</a> <span class="cs1-format">(PDF)</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=Tecentriq+PI&rft_id=https%3A%2F%2Fwww.guildlink.com.au%2Fgc%2Fws%2Fro%2Fpi.cfm%3Fproduct%3Droptecen10717&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.tga.gov.au/resources/publication/publications/prescription-medicines-registration-new-chemical-entities-australia-2017">"Prescription medicines: registration of new chemical entities in Australia, 2017"</a>. <i>Therapeutic Goods Administration (TGA)</i>. 21 June 2022<span class="reference-accessdate">. Retrieved <span class="nowrap">9 April</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Therapeutic+Goods+Administration+%28TGA%29&rft.atitle=Prescription+medicines%3A+registration+of+new+chemical+entities+in+Australia%2C+2017&rft.date=2022-06-21&rft_id=https%3A%2F%2Fwww.tga.gov.au%2Fresources%2Fpublication%2Fpublications%2Fprescription-medicines-registration-new-chemical-entities-australia-2017&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-3">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.tga.gov.au/resources/publication/publications/prescription-medicines-and-biologicals-tga-annual-summary-2017">"Prescription medicines and biologicals: TGA annual summary 2017"</a>. <i>Therapeutic Goods Administration (TGA)</i>. 21 June 2022<span class="reference-accessdate">. Retrieved <span class="nowrap">31 March</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Therapeutic+Goods+Administration+%28TGA%29&rft.atitle=Prescription+medicines+and+biologicals%3A+TGA+annual+summary+2017&rft.date=2022-06-21&rft_id=https%3A%2F%2Fwww.tga.gov.au%2Fresources%2Fpublication%2Fpublications%2Fprescription-medicines-and-biologicals-tga-annual-summary-2017&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-4">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://dhpp.hpfb-dgpsa.ca/review-documents/resource/RDS1711121589642">"Regulatory Decision Summary for Tecentriq / Tecentriq SC"</a>. <i>Drug and Health Products Portal</i>. 13 March 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">1 April</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drug+and+Health+Products+Portal&rft.atitle=Regulatory+Decision+Summary+for+Tecentriq+%2F+Tecentriq+SC&rft.date=2024-03-13&rft_id=https%3A%2F%2Fdhpp.hpfb-dgpsa.ca%2Freview-documents%2Fresource%2FRDS1711121589642&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://dhpp.hpfb-dgpsa.ca/dhpp/resource/95089">"Details for: Tecentriq"</a>. <i>Drug and Health Products Portal</i>. 2 May 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">1 April</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drug+and+Health+Products+Portal&rft.atitle=Details+for%3A+Tecentriq&rft.date=2017-05-02&rft_id=https%3A%2F%2Fdhpp.hpfb-dgpsa.ca%2Fdhpp%2Fresource%2F95089&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://dhpp.hpfb-dgpsa.ca/dhpp/resource/103502">"Details for: Tecentriq SC"</a>. <i>Drug and Health Products Portal</i>. 13 March 2024<span class="reference-accessdate">. Retrieved <span class="nowrap">1 April</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drug+and+Health+Products+Portal&rft.atitle=Details+for%3A+Tecentriq+SC&rft.date=2024-03-13&rft_id=https%3A%2F%2Fdhpp.hpfb-dgpsa.ca%2Fdhpp%2Fresource%2F103502&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.canada.ca/en/services/health/drug-health-products/drug-medical-device-highlights-2017/approved-drugs/cancer-therapies.html">"Cancer therapies"</a>. <i><a href="/wiki/Health_Canada" title="Health Canada">Health Canada</a></i>. 8 May 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">13 April</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Health+Canada&rft.atitle=Cancer+therapies&rft.date=2018-05-08&rft_id=https%3A%2F%2Fwww.canada.ca%2Fen%2Fservices%2Fhealth%2Fdrug-health-products%2Fdrug-medical-device-highlights-2017%2Fapproved-drugs%2Fcancer-therapies.html&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.medicines.org.uk/emc/product/8442/smpc">"Tecentriq 1,200 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC)"</a>. <i>(emc)</i><span class="reference-accessdate">. Retrieved <span class="nowrap">4 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=%28emc%29&rft.atitle=Tecentriq+1%2C200+mg+concentrate+for+solution+for+infusion+-+Summary+of+Product+Characteristics+%28SmPC%29&rft_id=https%3A%2F%2Fwww.medicines.org.uk%2Femc%2Fproduct%2F8442%2Fsmpc&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-Tecentriq_FDA_label-9"><span class="mw-cite-backlink">^ <a href="#cite_ref-Tecentriq_FDA_label_9-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Tecentriq_FDA_label_9-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Tecentriq_FDA_label_9-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee">"Tecentriq- atezolizumab injection, solution"</a>. <i>DailyMed</i>. 3 June 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=DailyMed&rft.atitle=Tecentriq-+atezolizumab+injection%2C+solution&rft.date=2020-06-03&rft_id=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D6fa682c9-a312-4932-9831-f286908660ee&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-Tecentriq_EPAR-10"><span class="mw-cite-backlink">^ <a href="#cite_ref-Tecentriq_EPAR_10-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Tecentriq_EPAR_10-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Tecentriq_EPAR_10-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Tecentriq_EPAR_10-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Tecentriq_EPAR_10-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq">"Tecentriq EPAR"</a>. <i>European Medicines Agency</i>. 29 September 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=European+Medicines+Agency&rft.atitle=Tecentriq+EPAR&rft.date=2017-09-29&rft_id=https%3A%2F%2Fwww.ema.europa.eu%2Fen%2Fmedicines%2Fhuman%2FEPAR%2Ftecentriq&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</span> </li> <li id="cite_note-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-11">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-approval-atezolizumab-alveolar-soft-part-sarcoma">"FDA grants approval to atezolizumab for alveolar soft part sarcoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 9 December 2022<span class="reference-accessdate">. Retrieved <span class="nowrap">20 December</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+grants+approval+to+atezolizumab+for+alveolar+soft+part+sarcoma&rft.date=2022-12-09&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-grants-approval-atezolizumab-alveolar-soft-part-sarcoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-Nature-12"><span class="mw-cite-backlink">^ <a href="#cite_ref-Nature_12-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Nature_12-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFMadhusoodanan2023" class="citation journal cs1">Madhusoodanan, Jyoti (9 August 2023). <a rel="nofollow" class="external text" href="https://www.nature.com/articles/d41586-023-02492-x">"How a controversial US drug policy could be harming cancer patients worldwide"</a>. <i>Nature</i>. <b>620</b> (7973): 264–267. <a href="/wiki/Bibcode_(identifier)" class="mw-redirect" title="Bibcode (identifier)">Bibcode</a>:<a rel="nofollow" class="external text" href="https://ui.adsabs.harvard.edu/abs/2023Natur.620..264M">2023Natur.620..264M</a>. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1038%2Fd41586-023-02492-x">10.1038/d41586-023-02492-x</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/37558845">37558845</a><span class="reference-accessdate">. Retrieved <span class="nowrap">21 August</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Nature&rft.atitle=How+a+controversial+US+drug+policy+could+be+harming+cancer+patients+worldwide&rft.volume=620&rft.issue=7973&rft.pages=264-267&rft.date=2023-08-09&rft_id=info%3Apmid%2F37558845&rft_id=info%3Adoi%2F10.1038%2Fd41586-023-02492-x&rft_id=info%3Abibcode%2F2023Natur.620..264M&rft.aulast=Madhusoodanan&rft.aufirst=Jyoti&rft_id=https%3A%2F%2Fwww.nature.com%2Farticles%2Fd41586-023-02492-x&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-GT2015-13"><span class="mw-cite-backlink">^ <a href="#cite_ref-GT2015_13-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-GT2015_13-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-GT2015_13-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-GT2015_13-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="http://immuno-oncologynews.com/2015/10/02/genentech-presents-positive-results-atezolizumab-advanced-bladder-cancer/">"Genentech Presents Positive Results of Atezolizumab in Advanced Bladder Cancer"</a>. 2 October 2015.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genentech+Presents+Positive+Results+of+Atezolizumab+in+Advanced+Bladder+Cancer&rft.date=2015-10-02&rft_id=http%3A%2F%2Fimmuno-oncologynews.com%2F2015%2F10%2F02%2Fgenentech-presents-positive-results-atezolizumab-advanced-bladder-cancer%2F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA-BC-2016-14"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA-BC-2016_14-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA-BC-2016_14-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA-BC-2016_14-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA-BC-2016_14-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-FDA-BC-2016_14-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-bladder-cancer">"FDA approves new, targeted treatment for bladder cancer"</a> (Press release). U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA). 18 May 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">20 May</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+approves+new%2C+targeted+treatment+for+bladder+cancer&rft.pub=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.date=2016-05-18&rft_id=https%3A%2F%2Fwww.fda.gov%2Fnews-events%2Fpress-announcements%2Ffda-approves-new-targeted-treatment-bladder-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://markets.ft.com/data/announce/detail?dockey=1330-1000908931en-6FOV162THB6786NU81SP96FJ49">"European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types – Company Announcement - FT.com"</a>. <i>markets.ft.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">5 March</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=markets.ft.com&rft.atitle=European+Commission+approves+Roche%27s+Tecentriq+SC%2C+the+EU%27s+first+PD-%28L%291+cancer+immunotherapy+subcutaneous+injection+for+multiple+cancer+types+%E2%80%93+Company+Announcement+-+FT.com&rft_id=https%3A%2F%2Fmarkets.ft.com%2Fdata%2Fannounce%2Fdetail%3Fdockey%3D1330-1000908931en-6FOV162THB6786NU81SP96FJ49&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer">"FDA approves atezolizumab as adjuvant treatment for non-small cell lung cancer"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 15 October 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">15 October</span> 2021</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+atezolizumab+as+adjuvant+treatment+for+non-small+cell+lung+cancer&rft.date=2021-10-15&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-atezolizumab-adjuvant-treatment-non-small-cell-lung-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.biopharmadive.com/news/roche-tecentriq-bladder-cancer-accelerated-withdrawal/637485/">"Roche pulls Tecentriq in bladder cancer, completing sweep of 'dangling' accelerated approvals"</a>. <i>BioPharma Dive</i><span class="reference-accessdate">. Retrieved <span class="nowrap">7 December</span> 2022</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=BioPharma+Dive&rft.atitle=Roche+pulls+Tecentriq+in+bladder+cancer%2C+completing+sweep+of+%27dangling%27+accelerated+approvals&rft_id=https%3A%2F%2Fwww.biopharmadive.com%2Fnews%2Froche-tecentriq-bladder-cancer-accelerated-withdrawal%2F637485%2F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><span title="www.drugs.com"><a rel="nofollow" class="external text" href="https://www.drugs.com/pro/tecentriq.html">FDA Professional Drug Information</a></span> for Tecentriq.</span> </li> <li id="cite_note-:1-19"><span class="mw-cite-backlink">^ <a href="#cite_ref-:1_19-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:1_19-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:1_19-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:1_19-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-:1_19-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-:1_19-5"><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-:1_19-6"><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-:1_19-7"><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-:1_19-8"><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-:1_19-9"><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-:1_19-10"><sup><i><b>k</b></i></sup></a> <a href="#cite_ref-:1_19-11"><sup><i><b>l</b></i></sup></a> <a href="#cite_ref-:1_19-12"><sup><i><b>m</b></i></sup></a> <a href="#cite_ref-:1_19-13"><sup><i><b>n</b></i></sup></a> <a href="#cite_ref-:1_19-14"><sup><i><b>o</b></i></sup></a> <a href="#cite_ref-:1_19-15"><sup><i><b>p</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFNasserGorenbergAgbarya2020" class="citation journal cs1">Nasser NJ, Gorenberg M, Agbarya A (November 2020). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695295">"First line Immunotherapy for Non-Small Cell Lung Cancer"</a>. <i>Pharmaceuticals</i>. <b>13</b> (11): 373. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.3390%2Fph13110373">10.3390/ph13110373</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695295">7695295</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/33171686">33171686</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Pharmaceuticals&rft.atitle=First+line+Immunotherapy+for+Non-Small+Cell+Lung+Cancer&rft.volume=13&rft.issue=11&rft.pages=373&rft.date=2020-11&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7695295%23id-name%3DPMC&rft_id=info%3Apmid%2F33171686&rft_id=info%3Adoi%2F10.3390%2Fph13110373&rft.aulast=Nasser&rft.aufirst=NJ&rft.au=Gorenberg%2C+M&rft.au=Agbarya%2C+A&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7695295&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span><span typeof="mw:File"><a href="/wiki/File:CC_BY_icon.svg" class="mw-file-description"><img src="//upload.wikimedia.org/wikipedia/commons/thumb/e/e1/CC_BY_icon.svg/50px-CC_BY_icon.svg.png" decoding="async" width="50" height="18" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/e1/CC_BY_icon.svg/75px-CC_BY_icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/e1/CC_BY_icon.svg/100px-CC_BY_icon.svg.png 2x" data-file-width="88" data-file-height="31" /></a></span> Text was copied from this source, which is available under a <a rel="nofollow" class="external text" href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution 4.0 International License</a>.</span> </li> <li id="cite_note-:0-20"><span class="mw-cite-backlink">^ <a href="#cite_ref-:0_20-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-:0_20-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-:0_20-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-:0_20-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFSynTengMokSoo2017" class="citation journal cs1">Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". <i>The Lancet. Oncology</i>. <b>18</b> (12): e731–e741. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fs1470-2045%2817%2930607-1">10.1016/s1470-2045(17)30607-1</a>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29208439">29208439</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=The+Lancet.+Oncology&rft.atitle=De-novo+and+acquired+resistance+to+immune+checkpoint+targeting&rft.volume=18&rft.issue=12&rft.pages=e731-e741&rft.date=2017-12&rft_id=info%3Adoi%2F10.1016%2Fs1470-2045%2817%2930607-1&rft_id=info%3Apmid%2F29208439&rft.aulast=Syn&rft.aufirst=NL&rft.au=Teng%2C+MW&rft.au=Mok%2C+TS&rft.au=Soo%2C+RA&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFShields2016" class="citation news cs1">Shields M (11 April 2016). <a rel="nofollow" class="external text" href="https://www.reuters.com/article/us-roche-atezolizumab-idUSKCN0X80F6">"Roche says FDA fast tracks atezolizumab in specific type of lung cancer"</a>. <i><a href="/wiki/Reuters" title="Reuters">Reuters</a></i><span class="reference-accessdate">. Retrieved <span class="nowrap">11 April</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Reuters&rft.atitle=Roche+says+FDA+fast+tracks+atezolizumab+in+specific+type+of+lung+cancer&rft.date=2016-04-11&rft.aulast=Shields&rft.aufirst=M&rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-roche-atezolizumab-idUSKCN0X80F6&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000TOC.cfm">"Tecentriq (atezolizumab) Injection"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 21 June 2016. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20191205075739/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000TOC.cfm">Archived</a> from the original on 5 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">4 December</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=Tecentriq+%28atezolizumab%29+Injection&rft.date=2016-06-21&rft_id=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Fnda%2F2016%2F761034Orig1s000TOC.cfm&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.healio.com/hematology-oncology/genitourinary-cancer/news/print/hemonc-today/%7B94ed7cf7-ff28-496d-8980-5e7618bf3e1b%7D/failed-confirmatory-trial-raises-questions-about-atezolizumab-for-advanced-urothelial-cancer">"Failed confirmatory trial raises questions about atezolizumab for advanced urothelial cancer"</a>. <i>HemOnc Today</i>. 25 June 2017.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=HemOnc+Today&rft.atitle=Failed+confirmatory+trial+raises+questions+about+atezolizumab+for+advanced+urothelial+cancer&rft.date=2017-06-25&rft_id=https%3A%2F%2Fwww.healio.com%2Fhematology-oncology%2Fgenitourinary-cancer%2Fnews%2Fprint%2Fhemonc-today%2F%257B94ed7cf7-ff28-496d-8980-5e7618bf3e1b%257D%2Ffailed-confirmatory-trial-raises-questions-about-atezolizumab-for-advanced-urothelial-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancer.gov/news-events/cancer-currents-blog/2018/bladder-cancer-checkpoint-inhibitor-change">"Checkpoint Inhibitor Use Changed for Bladder Cancer"</a>. <i>National Cancer Institute</i>. 26 July 2018.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=National+Cancer+Institute&rft.atitle=Checkpoint+Inhibitor+Use+Changed+for+Bladder+Cancer&rft.date=2018-07-26&rft_id=https%3A%2F%2Fwww.cancer.gov%2Fnews-events%2Fcancer-currents-blog%2F2018%2Fbladder-cancer-checkpoint-inhibitor-change&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA_20160518-25"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_20160518_25-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_20160518_25-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/atezolizumab-urothelial-carcinoma">"Atezolizumab for Urothelial Carcinoma"</a>. <i>U.S. Food and Drug Administration</i>. 18 May 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration&rft.atitle=Atezolizumab+for+Urothelial+Carcinoma&rft.date=2016-05-18&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Fatezolizumab-urothelial-carcinoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="http://www.fiercepharma.com/pharma/roche-s-shocking-tecentriq-fail-raises-red-flag-for-bladder-cancer-rivals">"Roche's shocking Tecentriq fail raises red flag for bladder cancer rivals"</a>. <i>Fierce Pharma</i>. 10 May 2017<span class="reference-accessdate">. Retrieved <span class="nowrap">11 May</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Fierce+Pharma&rft.atitle=Roche%27s+shocking+Tecentriq+fail+raises+red+flag+for+bladder+cancer+rivals&rft.date=2017-05-10&rft_id=http%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Froche-s-shocking-tecentriq-fail-raises-red-flag-for-bladder-cancer-rivals&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA_snapshot-27"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_snapshot_27-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_snapshot_27-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-tecentriq">"Drug Trials Snapshots: Tecentriq"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 18 May 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=Drug+Trials+Snapshots%3A+Tecentriq&rft.date=2016-05-18&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Fdrug-trials-snapshots-tecentriq&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-FDA-10-18-2016-28"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA-10-18-2016_28-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA-10-18-2016_28-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA-10-18-2016_28-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-FDA-10-18-2016_28-3"><sup><i><b>d</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/atezolizumab-tecentriq">"FDA approves new treatment for non-small cell lung cancer"</a>. U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA). 18 October 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">18 May</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+approves+new+treatment+for+non-small+cell+lung+cancer&rft.pub=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.date=2016-10-18&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Fatezolizumab-tecentriq&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFMcKee2018" class="citation web cs1">McKee S (8 May 2018). <a rel="nofollow" class="external text" href="https://www.pharmatimes.com/news/first-line_use_of_roches_tecentriq_given_priority_review_1234653">"First-line use of Roche's Tecentriq given priority review"</a>. <i>PharmaTimes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">8 May</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=PharmaTimes&rft.atitle=First-line+use+of+Roche%27s+Tecentriq+given+priority+review&rft.date=2018-05-08&rft.aulast=McKee&rft.aufirst=S&rft_id=https%3A%2F%2Fwww.pharmatimes.com%2Fnews%2Ffirst-line_use_of_roches_tecentriq_given_priority_review_1234653&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-30">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-updates-prescribing-information-keytruda-and-tecentriq">"FDA updates prescribing information for Keytruda and Tecentriq"</a>. <i>U.S. Food and Drug Administration</i>. 16 August 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration&rft.atitle=FDA+updates+prescribing+information+for+Keytruda+and+Tecentriq&rft.date=2018-08-16&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-updates-prescribing-information-keytruda-and-tecentriq&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFSchmidAdamsRugoSchneeweiss2018" class="citation journal cs1">Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. (November 2018). <a rel="nofollow" class="external text" href="https://doi.org/10.1056%2Fnejmoa1809615">"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer"</a>. <i>The New England Journal of Medicine</i>. <b>379</b> (22): 2108–2121. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1056%2Fnejmoa1809615">10.1056/nejmoa1809615</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/30345906">30345906</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=The+New+England+Journal+of+Medicine&rft.atitle=Atezolizumab+and+Nab-Paclitaxel+in+Advanced+Triple-Negative+Breast+Cancer&rft.volume=379&rft.issue=22&rft.pages=2108-2121&rft.date=2018-11&rft_id=info%3Adoi%2F10.1056%2Fnejmoa1809615&rft_id=info%3Apmid%2F30345906&rft.aulast=Schmid&rft.aufirst=P&rft.au=Adams%2C+S&rft.au=Rugo%2C+HS&rft.au=Schneeweiss%2C+A&rft.au=Barrios%2C+CH&rft.au=Iwata%2C+H&rft.au=Di%C3%A9ras%2C+V&rft.au=Hegg%2C+R&rft.au=Im%2C+SA&rft.au=Shaw+Wright%2C+G&rft.au=Henschel%2C+V&rft.au=Molinero%2C+L&rft.au=Chui%2C+SY&rft.au=Funke%2C+R&rft.au=Husain%2C+A&rft.au=Winer%2C+EP&rft.au=Loi%2C+S&rft.au=Emens%2C+LA&rft_id=https%3A%2F%2Fdoi.org%2F10.1056%252Fnejmoa1809615&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA_PR_December_2016-32"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_December_2016_32-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_December_2016_32-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/fda-approves-atezolizumab-chemotherapy-and-bevacizumab-first-line-treatment-metastatic-non-squamous">"FDA approves atezolizumab with chemotherapy and bevacizumab for first-"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 6 December 2018<span class="reference-accessdate">. Retrieved <span class="nowrap">4 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+atezolizumab+with+chemotherapy+and+bevacizumab+for+first-&rft.date=2018-12-06&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Ffda-approves-atezolizumab-chemotherapy-and-bevacizumab-first-line-treatment-metastatic-non-squamous&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.statnews.com/2019/03/08/roche-tecentriq-first-breast-cancer-immunotherapy/">"Roche scores first U.S. approval of immunotherapy for breast cancer"</a>. <i><a href="/wiki/Stat_(website)" title="Stat (website)">Stat</a></i>. 9 March 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">9 March</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Stat&rft.atitle=Roche+scores+first+U.S.+approval+of+immunotherapy+for+breast+cancer&rft.date=2019-03-09&rft_id=https%3A%2F%2Fwww.statnews.com%2F2019%2F03%2F08%2Froche-tecentriq-first-breast-cancer-immunotherapy%2F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA_PR_20190308-34"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_20190308_34-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_20190308_34-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_PR_20190308_34-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative">"FDA approves atezolizumab for PD-L1 positive unresectable locally advanced or metastatic triple-negative breast cancer"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i> (Press release). 18 March 2019. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20191205075230/https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative">Archived</a> from the original on 5 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">4 December</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+approves+atezolizumab+for+PD-L1+positive+unresectable+locally+advanced+or+metastatic+triple-negative+breast+cancer&rft.date=2019-03-18&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Ffda-approves-atezolizumab-pd-l1-positive-unresectable-locally-advanced-or-metastatic-triple-negative&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-FDA_PR_20190319-35"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_20190319_35-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_20190319_35-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-extensive-stage-small-cell-lung-cancer">"FDA approves atezolizumab for extensive-stage small cell lung cancer"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 19 March 2019. <a rel="nofollow" class="external text" href="https://web.archive.org/web/20191205081145/https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-extensive-stage-small-cell-lung-cancer">Archived</a> from the original on 5 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">5 December</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+atezolizumab+for+extensive-stage+small+cell+lung+cancer&rft.date=2019-03-19&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Ffda-approves-atezolizumab-extensive-stage-small-cell-lung-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-FDA_PR_20191203-36"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_20191203_36-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_20191203_36-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_PR_20191203_36-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk">"FDA approves atezolizumab with nab-paclitaxel and carboplatin for metastatic NSCLC without EGFR/ALK aberrations"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i> (Press release). 3 December 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+approves+atezolizumab+with+nab-paclitaxel+and+carboplatin+for+metastatic+NSCLC+without+EGFR%2FALK+aberrations&rft.date=2019-12-03&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-atezolizumab-nab-paclitaxel-and-carboplatin-metastatic-nsclc-without-egfralk&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-FDA_PR_20200518-37"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_20200518_37-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_20200518_37-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_PR_20200518_37-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression">"FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 18 May 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+atezolizumab+for+first-line+treatment+of+metastatic+NSCLC+with+high+PD-L1+expression&rft.date=2020-05-18&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-FDA_PR_20200529-38"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_20200529_38-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_20200529_38-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_PR_20200529_38-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma">"FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a> (FDA)</i>. 29 May 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=U.S.+Food+and+Drug+Administration+%28FDA%29&rft.atitle=FDA+approves+atezolizumab+plus+bevacizumab+for+unresectable+hepatocellular+carcinoma&rft.date=2020-05-29&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdrug-approvals-and-databases%2Ffda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-FDA_PR_20200730-39"><span class="mw-cite-backlink">^ <a href="#cite_ref-FDA_PR_20200730_39-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_PR_20200730_39-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-FDA_PR_20200730_39-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation pressrelease cs1"><a rel="nofollow" class="external text" href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma">"FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma"</a>. <i>U.S. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a></i> (Press release). 30 July 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">31 July</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=FDA+approves+atezolizumab+for+BRAF+V600+unresectable+or+metastatic+melanoma&rft.date=2020-07-30&rft_id=https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fresources-information-approved-drugs%2Ffda-approves-atezolizumab-braf-v600-unresectable-or-metastatic-melanoma&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span> <span class="noviewer" typeof="mw:File"><span><img alt="Public Domain" src="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/12px-PD-icon.svg.png" decoding="async" width="12" height="12" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/18px-PD-icon.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/6/62/PD-icon.svg/24px-PD-icon.svg.png 2x" data-file-width="196" data-file-height="196" /></span></span> This article incorporates text from this source, which is in the <a href="/wiki/Public_domain" title="Public domain">public domain</a>.</span> </li> <li id="cite_note-40"><span class="mw-cite-backlink"><b><a href="#cite_ref-40">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFSocinskiJotteCappuzzoOrlandi2018" class="citation journal cs1">Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. (June 2018). <a rel="nofollow" class="external text" href="https://doi.org/10.1056%2FNEJMoa1716948">"Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC"</a>. <i>The New England Journal of Medicine</i>. <b>378</b> (24): 2288–2301. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1056%2FNEJMoa1716948">10.1056/NEJMoa1716948</a></span>. <a href="/wiki/Hdl_(identifier)" class="mw-redirect" title="Hdl (identifier)">hdl</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://hdl.handle.net/10553%2F41871">10553/41871</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/29863955">29863955</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=The+New+England+Journal+of+Medicine&rft.atitle=Atezolizumab+for+First-Line+Treatment+of+Metastatic+Nonsquamous+NSCLC&rft.volume=378&rft.issue=24&rft.pages=2288-2301&rft.date=2018-06&rft_id=info%3Ahdl%2F10553%2F41871&rft_id=info%3Apmid%2F29863955&rft_id=info%3Adoi%2F10.1056%2FNEJMoa1716948&rft.aulast=Socinski&rft.aufirst=MA&rft.au=Jotte%2C+RM&rft.au=Cappuzzo%2C+F&rft.au=Orlandi%2C+F&rft.au=Stroyakovskiy%2C+D&rft.au=Nogami%2C+N&rft.au=Rodr%C3%ADguez-Abreu%2C+D&rft.au=Moro-Sibilot%2C+D&rft.au=Thomas%2C+CA&rft.au=Barlesi%2C+F&rft.au=Finley%2C+G&rft.au=Kelsch%2C+C&rft.au=Lee%2C+A&rft.au=Coleman%2C+S&rft.au=Deng%2C+Y&rft.au=Shen%2C+Y&rft.au=Kowanetz%2C+M&rft.au=Lopez-Chavez%2C+A&rft.au=Sandler%2C+A&rft.au=Reck%2C+M&rft_id=https%3A%2F%2Fdoi.org%2F10.1056%252FNEJMoa1716948&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-41"><span class="mw-cite-backlink"><b><a href="#cite_ref-41">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFReckWehlerOrlandiNogami2020" class="citation journal cs1">Reck M, Wehler T, Orlandi F, Nogami N, Barone C, Moro-Sibilot D, et al. (August 2020). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392741">"Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non-Small-Cell Lung Cancer"</a>. <i>Journal of Clinical Oncology</i>. <b>38</b> (22): 2530–2542. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1200%2FJCO.19.03158">10.1200/JCO.19.03158</a>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392741">7392741</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/32459597">32459597</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Journal+of+Clinical+Oncology&rft.atitle=Safety+and+Patient-Reported+Outcomes+of+Atezolizumab+Plus+Chemotherapy+With+or+Without+Bevacizumab+Versus+Bevacizumab+Plus+Chemotherapy+in+Non-Small-Cell+Lung+Cancer&rft.volume=38&rft.issue=22&rft.pages=2530-2542&rft.date=2020-08&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7392741%23id-name%3DPMC&rft_id=info%3Apmid%2F32459597&rft_id=info%3Adoi%2F10.1200%2FJCO.19.03158&rft.aulast=Reck&rft.aufirst=M&rft.au=Wehler%2C+T&rft.au=Orlandi%2C+F&rft.au=Nogami%2C+N&rft.au=Barone%2C+C&rft.au=Moro-Sibilot%2C+D&rft.au=Shtivelband%2C+M&rft.au=Gonz%C3%A1lez+Larriba%2C+JL&rft.au=Rothenstein%2C+J&rft.au=Fr%C3%BCh%2C+M&rft.au=Yu%2C+W&rft.au=Deng%2C+Y&rft.au=Coleman%2C+S&rft.au=Shankar%2C+G&rft.au=Patel%2C+H&rft.au=Kelsch%2C+C&rft.au=Lee%2C+A&rft.au=Piault%2C+E&rft.au=Socinski%2C+MA&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC7392741&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation news cs1"><a rel="nofollow" class="external text" href="https://www.onclive.com/view/subcutaneous-atezolizumab-approved-in-great-britain-for-all-intravenous-indications">"Subcutaneous Atezolizumab Approved in Great Britain for All Intravenous Indications"</a>. <i>OncLive</i>. 29 August 2023<span class="reference-accessdate">. Retrieved <span class="nowrap">11 September</span> 2023</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=OncLive&rft.atitle=Subcutaneous+Atezolizumab+Approved+in+Great+Britain+for+All+Intravenous+Indications&rft.date=2023-08-29&rft_id=https%3A%2F%2Fwww.onclive.com%2Fview%2Fsubcutaneous-atezolizumab-approved-in-great-britain-for-all-intravenous-indications&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.roche.com/media/releases/med-cor-2024-01-16">"European Commission approves Roche's Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types"</a>. <i>www.roche.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">5 March</span> 2024</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=www.roche.com&rft.atitle=European+Commission+approves+Roche%27s+Tecentriq+SC%2C+the+EU%27s+first+PD-%28L%291+cancer+immunotherapy+subcutaneous+injection+for+multiple+cancer+types&rft_id=https%3A%2F%2Fwww.roche.com%2Fmedia%2Freleases%2Fmed-cor-2024-01-16&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-44"><span class="mw-cite-backlink"><b><a href="#cite_ref-44">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.drugs.com/medical-answers/cost-tecentriq-3064818/">"What is the cost of Tecentriq?"</a>. <i>Drugs.com</i>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Drugs.com&rft.atitle=What+is+the+cost+of+Tecentriq%3F&rft_id=https%3A%2F%2Fwww.drugs.com%2Fmedical-answers%2Fcost-tecentriq-3064818%2F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.tecentriq-hcp.com/sclc/clinical-data-efficacy/study-efficacy.html">"SCLC"</a>. <i>Tecentriq</i><span class="reference-accessdate">. Retrieved <span class="nowrap">4 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Tecentriq&rft.atitle=SCLC&rft_id=https%3A%2F%2Fwww.tecentriq-hcp.com%2Fsclc%2Fclinical-data-efficacy%2Fstudy-efficacy.html&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFMartell2020" class="citation news cs1">Martell A (20 February 2020). <a rel="nofollow" class="external text" href="https://www.reuters.com/article/us-canada-pharmaceuticals-exclusive/exclusive-canadian-regulator-considers-changes-to-new-drug-pricing-plan-idUSKBN20E2LI">"Exclusive: Canadian regulator considers changes to new drug pricing plan"</a>. <i>Reuters</i><span class="reference-accessdate">. Retrieved <span class="nowrap">4 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Reuters&rft.atitle=Exclusive%3A+Canadian+regulator+considers+changes+to+new+drug+pricing+plan&rft.date=2020-02-20&rft.aulast=Martell&rft.aufirst=A&rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-canada-pharmaceuticals-exclusive%2Fexclusive-canadian-regulator-considers-changes-to-new-drug-pricing-plan-idUSKBN20E2LI&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><span class="id-lock-registration" title="Free registration required"><a rel="nofollow" class="external text" href="https://www.onclive.com/web-exclusives/nice-cites-cost-in-deciding-against-atezolizumab-for-frontline-advanced-small-cell-lung-cancer">"NICE Cites Cost in Deciding Against Atezolizumab for Frontline Advanced Small Cell Lung Cancer"</a></span>. <i>OncLive</i>. 6 January 2020<span class="reference-accessdate">. Retrieved <span class="nowrap">4 March</span> 2020</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=OncLive&rft.atitle=NICE+Cites+Cost+in+Deciding+Against+Atezolizumab+for+Frontline+Advanced+Small+Cell+Lung+Cancer&rft.date=2020-01-06&rft_id=https%3A%2F%2Fwww.onclive.com%2Fweb-exclusives%2Fnice-cites-cost-in-deciding-against-atezolizumab-for-frontline-advanced-small-cell-lung-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.nice.org.uk/news/article/nice-recommends-treatment-for-type-of-small-cell-lung-cancer">"NICE recommends treatment for type of small-cell lung cancer"</a>. 27 May 2020.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=NICE+recommends+treatment+for+type+of+small-cell+lung+cancer&rft.date=2020-05-27&rft_id=https%3A%2F%2Fwww.nice.org.uk%2Fnews%2Farticle%2Fnice-recommends-treatment-for-type-of-small-cell-lung-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://pharmaphorum.com/news/nice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink/">"NICE recommends Roche's Tecentriq in ES-SCLC following price rethink"</a>. 27 May 2020.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=unknown&rft.btitle=NICE+recommends+Roche%27s+Tecentriq+in+ES-SCLC+following+price+rethink&rft.date=2020-05-27&rft_id=https%3A%2F%2Fpharmaphorum.com%2Fnews%2Fnice-recommends-roches-tecentriq-in-es-sclc-following-price-rethink%2F&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-NCT-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-NCT_50-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/ct2/results?cond=&term=MPDL3280A&cntry=&state=&city=&dist=">"Search of: MPDL3280A"</a>. <i>ClinialTrialsGov</i>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=ClinialTrialsGov&rft.atitle=Search+of%3A+MPDL3280A&rft_id=https%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fresults%3Fcond%3D%26term%3DMPDL3280A%26cntry%3D%26state%3D%26city%3D%26dist%3D&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-51"><span class="mw-cite-backlink"><b><a href="#cite_ref-51">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="CITEREFBendellKimGohWallin" class="citation conference cs1">Bendell JC, Kim TW, Goh BC, Wallin J, Oh DY, Han SW, et al. <a rel="nofollow" class="external text" href="https://meetinglibrary.asco.org/record/123622/abstract"><i>Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC)</i></a>. 2016 ASCO Annual Meeting.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&rft.genre=conference&rft.btitle=Clinical+activity+and+safety+of+cobimetinib+%28cobi%29+and+atezolizumab+in+colorectal+cancer+%28CRC%29&rft.aulast=Bendell&rft.aufirst=JC&rft.au=Kim%2C+TW&rft.au=Goh%2C+BC&rft.au=Wallin%2C+J&rft.au=Oh%2C+DY&rft.au=Han%2C+SW&rft.au=Lee%2C+CB&rft.au=Hellmann%2C+MD&rft.au=Desai%2C+J&rft.au=Lewin%2C+JH&rft.au=Solomon%2C+BJ&rft_id=https%3A%2F%2Fmeetinglibrary.asco.org%2Frecord%2F123622%2Fabstract&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-atezolizumab_in_the_treatment_of_metastatic_non-small-cell_lung_cancer-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-atezolizumab_in_the_treatment_of_metastatic_non-small-cell_lung_cancer_52-0">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite id="15" class="citation journal cs1">Facchinetti F, Bordi P, Leonetti A, Buti S, Tiseo M (10 September 2018). <a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137949">"Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives"</a>. <i>Drug Design, Development and Therapy</i>. <b>12</b>: 2857–2873. <a href="/wiki/Doi_(identifier)" class="mw-redirect" title="Doi (identifier)">doi</a>:<span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.2147%2FDDDT.S124380">10.2147/DDDT.S124380</a></span>. <a href="/wiki/PMC_(identifier)" class="mw-redirect" title="PMC (identifier)">PMC</a> <span class="id-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6137949">6137949</a></span>. <a href="/wiki/PMID_(identifier)" class="mw-redirect" title="PMID (identifier)">PMID</a> <a rel="nofollow" class="external text" href="https://pubmed.ncbi.nlm.nih.gov/30237696">30237696</a>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.jtitle=Drug+Design%2C+Development+and+Therapy&rft.atitle=Profile+of+atezolizumab+in+the+treatment+of+metastatic+non-small-cell+lung+cancer%3A+patient+selection+and+perspectives&rft.volume=12&rft.pages=2857-2873&rft.date=2018-09-10&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6137949%23id-name%3DPMC&rft_id=info%3Apmid%2F30237696&rft_id=info%3Adoi%2F10.2147%2FDDDT.S124380&rft.aulast=Facchinetti&rft.aufirst=F&rft.au=Bordi%2C+P&rft.au=Leonetti%2C+A&rft.au=Buti%2C+S&rft.au=Tiseo%2C+M&rft_id=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC6137949&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-53"><span class="mw-cite-backlink"><b><a href="#cite_ref-53">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancernetwork.com/view/mpdl3280a-shows-activity-triple-negative-breast-cancer">"MPDL3280A Shows Activity in Triple-Negative Breast Cancer"</a>. <i>Cancer Network</i>. 20 April 2015.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Cancer+Network&rft.atitle=MPDL3280A+Shows+Activity+in+Triple-Negative+Breast+Cancer&rft.date=2015-04-20&rft_id=https%3A%2F%2Fwww.cancernetwork.com%2Fview%2Fmpdl3280a-shows-activity-triple-negative-breast-cancer&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> <li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20210428121249/https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm">"Product Development Portfolio"</a>. <i>Roche</i>. Archived from <a rel="nofollow" class="external text" href="https://www.roche.com/research_and_development/who_we_are_how_we_work/pipeline.htm">the original</a> on 28 April 2021<span class="reference-accessdate">. Retrieved <span class="nowrap">27 February</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=Roche&rft.atitle=Product+Development+Portfolio&rft_id=https%3A%2F%2Fwww.roche.com%2Fresearch_and_development%2Fwho_we_are_how_we_work%2Fpipeline.htm&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></span> </li> </ol></div></div> <div class="mw-heading mw-heading2"><h2 id="External_links">External links</h2><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=10" title="Edit section: External links"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <ul><li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/atezolizumab">"Atezolizumab"</a>. <i>NCI Drug Dictionary</i>. National Cancer Institute.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=NCI+Drug+Dictionary&rft.atitle=Atezolizumab&rft_id=https%3A%2F%2Fwww.cancer.gov%2Fpublications%2Fdictionaries%2Fcancer-drug%2Fdef%2Fatezolizumab&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></li> <li><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1238218222"><cite class="citation web cs1"><a rel="nofollow" class="external text" href="https://www.cancer.gov/about-cancer/treatment/drugs/atezolizumab">"Atezolizumab"</a>. <i>National Cancer Institute</i>. 20 May 2016.</cite><span title="ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=unknown&rft.jtitle=National+Cancer+Institute&rft.atitle=Atezolizumab&rft.date=2016-05-20&rft_id=https%3A%2F%2Fwww.cancer.gov%2Fabout-cancer%2Ftreatment%2Fdrugs%2Fatezolizumab&rfr_id=info%3Asid%2Fen.wikipedia.org%3AAtezolizumab" class="Z3988"></span></li></ul> <div class="mw-heading mw-heading3"><h3 id="Clinical_trials">Clinical trials</h3><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Atezolizumab&action=edit&section=11" title="Edit section: Clinical trials"><span>edit</span></a><span class="mw-editsection-bracket">]</span></span></div> <ul><li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02541604">NCT02541604</a></i> for "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02951767">NCT02951767</a></i> for "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02807636">NCT02807636</a></i> for "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02409342">NCT02409342</a></i> for "A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02366143">NCT02366143</a></i> for "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower150)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02367781">NCT02367781</a></i> for "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower130)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02008227">NCT02008227</a></i> for "A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy (OAK)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02425891">NCT02425891</a></i> for "A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT03125902">NCT03125902</a></i> for "A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02763579">NCT02763579</a></i> for "A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) (IMpower133)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT03434379">NCT03434379</a></i> for "A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150] (IMbrave150)" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02908672">NCT02908672</a></i> for "A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li> <li>Clinical trial number <i><a rel="nofollow" class="external text" href="https://www.clinicaltrials.gov/show/NCT02486718">NCT02486718</a></i> for "Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]" at <a href="/wiki/ClinicalTrials.gov" title="ClinicalTrials.gov">ClinicalTrials.gov</a></li></ul> <div class="navbox-styles"><style data-mw-deduplicate="TemplateStyles:r1129693374">.mw-parser-output .hlist dl,.mw-parser-output .hlist ol,.mw-parser-output .hlist ul{margin:0;padding:0}.mw-parser-output .hlist dd,.mw-parser-output .hlist dt,.mw-parser-output .hlist li{margin:0;display:inline}.mw-parser-output .hlist.inline,.mw-parser-output .hlist.inline dl,.mw-parser-output .hlist.inline ol,.mw-parser-output .hlist.inline ul,.mw-parser-output .hlist dl dl,.mw-parser-output .hlist dl ol,.mw-parser-output .hlist dl ul,.mw-parser-output .hlist ol dl,.mw-parser-output .hlist ol ol,.mw-parser-output .hlist ol ul,.mw-parser-output .hlist ul dl,.mw-parser-output .hlist ul ol,.mw-parser-output .hlist ul ul{display:inline}.mw-parser-output .hlist .mw-empty-li{display:none}.mw-parser-output .hlist dt::after{content:": "}.mw-parser-output .hlist dd::after,.mw-parser-output .hlist li::after{content:" · ";font-weight:bold}.mw-parser-output .hlist dd:last-child::after,.mw-parser-output .hlist dt:last-child::after,.mw-parser-output .hlist li:last-child::after{content:none}.mw-parser-output .hlist dd dd:first-child::before,.mw-parser-output .hlist dd dt:first-child::before,.mw-parser-output .hlist dd li:first-child::before,.mw-parser-output .hlist dt dd:first-child::before,.mw-parser-output .hlist dt dt:first-child::before,.mw-parser-output .hlist dt li:first-child::before,.mw-parser-output .hlist li dd:first-child::before,.mw-parser-output .hlist li dt:first-child::before,.mw-parser-output .hlist li li:first-child::before{content:" (";font-weight:normal}.mw-parser-output .hlist dd dd:last-child::after,.mw-parser-output .hlist dd dt:last-child::after,.mw-parser-output .hlist dd li:last-child::after,.mw-parser-output .hlist dt dd:last-child::after,.mw-parser-output .hlist dt dt:last-child::after,.mw-parser-output .hlist dt li:last-child::after,.mw-parser-output .hlist li dd:last-child::after,.mw-parser-output .hlist li dt:last-child::after,.mw-parser-output .hlist li li:last-child::after{content:")";font-weight:normal}.mw-parser-output .hlist ol{counter-reset:listitem}.mw-parser-output .hlist ol>li{counter-increment:listitem}.mw-parser-output .hlist ol>li::before{content:" "counter(listitem)"\a0 "}.mw-parser-output .hlist dd ol>li:first-child::before,.mw-parser-output .hlist dt ol>li:first-child::before,.mw-parser-output .hlist li ol>li:first-child::before{content:" ("counter(listitem)"\a0 "}</style><style data-mw-deduplicate="TemplateStyles:r1236075235">.mw-parser-output .navbox{box-sizing:border-box;border:1px solid #a2a9b1;width:100%;clear:both;font-size:88%;text-align:center;padding:1px;margin:1em auto 0}.mw-parser-output .navbox .navbox{margin-top:0}.mw-parser-output .navbox+.navbox,.mw-parser-output .navbox+.navbox-styles+.navbox{margin-top:-1px}.mw-parser-output .navbox-inner,.mw-parser-output .navbox-subgroup{width:100%}.mw-parser-output .navbox-group,.mw-parser-output .navbox-title,.mw-parser-output .navbox-abovebelow{padding:0.25em 1em;line-height:1.5em;text-align:center}.mw-parser-output .navbox-group{white-space:nowrap;text-align:right}.mw-parser-output .navbox,.mw-parser-output .navbox-subgroup{background-color:#fdfdfd}.mw-parser-output .navbox-list{line-height:1.5em;border-color:#fdfdfd}.mw-parser-output .navbox-list-with-group{text-align:left;border-left-width:2px;border-left-style:solid}.mw-parser-output tr+tr>.navbox-abovebelow,.mw-parser-output tr+tr>.navbox-group,.mw-parser-output tr+tr>.navbox-image,.mw-parser-output tr+tr>.navbox-list{border-top:2px solid #fdfdfd}.mw-parser-output .navbox-title{background-color:#ccf}.mw-parser-output .navbox-abovebelow,.mw-parser-output .navbox-group,.mw-parser-output .navbox-subgroup .navbox-title{background-color:#ddf}.mw-parser-output .navbox-subgroup .navbox-group,.mw-parser-output .navbox-subgroup .navbox-abovebelow{background-color:#e6e6ff}.mw-parser-output .navbox-even{background-color:#f7f7f7}.mw-parser-output .navbox-odd{background-color:transparent}.mw-parser-output .navbox .hlist td dl,.mw-parser-output .navbox .hlist td ol,.mw-parser-output .navbox .hlist td ul,.mw-parser-output .navbox td.hlist dl,.mw-parser-output .navbox td.hlist ol,.mw-parser-output .navbox td.hlist ul{padding:0.125em 0}.mw-parser-output .navbox .navbar{display:block;font-size:100%}.mw-parser-output .navbox-title .navbar{float:left;text-align:left;margin-right:0.5em}body.skin--responsive .mw-parser-output .navbox-image img{max-width:none!important}@media print{body.ns-0 .mw-parser-output .navbox{display:none!important}}</style></div><div role="navigation" class="navbox" aria-labelledby="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><style data-mw-deduplicate="TemplateStyles:r1239400231">.mw-parser-output .navbar{display:inline;font-size:88%;font-weight:normal}.mw-parser-output .navbar-collapse{float:left;text-align:left}.mw-parser-output .navbar-boxtext{word-spacing:0}.mw-parser-output .navbar ul{display:inline-block;white-space:nowrap;line-height:inherit}.mw-parser-output .navbar-brackets::before{margin-right:-0.125em;content:"[ "}.mw-parser-output .navbar-brackets::after{margin-left:-0.125em;content:" ]"}.mw-parser-output .navbar li{word-spacing:-0.125em}.mw-parser-output .navbar a>span,.mw-parser-output .navbar a>abbr{text-decoration:inherit}.mw-parser-output .navbar-mini abbr{font-variant:small-caps;border-bottom:none;text-decoration:none;cursor:inherit}.mw-parser-output .navbar-ct-full{font-size:114%;margin:0 7em}.mw-parser-output .navbar-ct-mini{font-size:114%;margin:0 4em}html.skin-theme-clientpref-night .mw-parser-output .navbar li a abbr{color:var(--color-base)!important}@media(prefers-color-scheme:dark){html.skin-theme-clientpref-os .mw-parser-output .navbar li a abbr{color:var(--color-base)!important}}@media print{.mw-parser-output .navbar{display:none!important}}</style><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Targeted_cancer_therapeutic_agents" title="Template:Targeted cancer therapeutic agents"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Targeted_cancer_therapeutic_agents" title="Template talk:Targeted cancer therapeutic agents"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:Targeted_cancer_therapeutic_agents" title="Special:EditPage/Template:Targeted cancer therapeutic agents"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="Targeted_cancer_therapy_/_antineoplastic_agents_(L01)" style="font-size:114%;margin:0 4em"><a href="/wiki/Targeted_cancer_therapy" class="mw-redirect" title="Targeted cancer therapy">Targeted cancer therapy</a> / <a href="/wiki/Antineoplastic" class="mw-redirect" title="Antineoplastic">antineoplastic agents</a> (<a href="/wiki/ATC_code_L01" title="ATC code L01">L01</a>)</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Cancer_immunotherapy" title="Cancer immunotherapy">CI</a> <a href="/wiki/Monoclonal_antibody_therapy" title="Monoclonal antibody therapy">monoclonal antibodies</a> ("-mab")</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Receptor_tyrosine_kinase" title="Receptor tyrosine kinase">Receptor tyrosine kinase</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/ErbB" title="ErbB">ErbB</a>: <i><a href="/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">HER1/EGFR</a></i> (<a href="/wiki/Cetuximab" title="Cetuximab">Cetuximab</a></li> <li><a href="/wiki/Panitumumab" title="Panitumumab">Panitumumab</a>)</li> <li><i><a href="/wiki/HER2/neu" class="mw-redirect" title="HER2/neu">HER2/neu</a></i> (<a href="/wiki/Pertuzumab" title="Pertuzumab">Pertuzumab</a></li> <li><a href="/wiki/Trastuzumab" title="Trastuzumab">Trastuzumab</a> (<a href="/wiki/Trastuzumab/hyaluronidase" title="Trastuzumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/wiki/Trastuzumab_emtansine" title="Trastuzumab emtansine">Trastuzumab emtansine</a></li> <li><a href="/wiki/Trastuzumab_deruxtecan" title="Trastuzumab deruxtecan">Trastuzumab deruxtecan</a></li> <li><a href="/wiki/Zanidatamab" title="Zanidatamab">Zanidatamab</a> )</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Others for solid tumors</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/EpCAM" class="mw-redirect" title="EpCAM">EpCAM</a></i> (<a href="/wiki/Catumaxomab" title="Catumaxomab">Catumaxomab</a></li> <li><a href="/wiki/Edrecolomab" title="Edrecolomab">Edrecolomab</a>)</li> <li><i><a href="/wiki/Vascular_endothelial_growth_factor_A" title="Vascular endothelial growth factor A">VEGF-A</a></i> (<a href="/wiki/Bevacizumab" title="Bevacizumab">Bevacizumab</a>)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Leukemia" title="Leukemia">Leukemia</a>/<a href="/wiki/Lymphoma" title="Lymphoma">lymphoma</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Lymphatic_system" title="Lymphatic system">lymphoid</a>: <i><a href="/wiki/CD3_(immunology)" title="CD3 (immunology)">CD3</a></i> (<a href="/wiki/Glofitamab" title="Glofitamab">Glofitamab</a>, <a href="/wiki/Elranatamab" title="Elranatamab">Elranatamab</a>, <a href="/wiki/Mosunetuzumab" title="Mosunetuzumab">Mosunetuzumab</a>), <i><a href="/wiki/CD20" title="CD20">CD20</a></i> (<a href="/wiki/Glofitamab" title="Glofitamab">Glofitamab</a></li> <li><a href="/wiki/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab</a></li> <li><a href="/wiki/Mosunetuzumab" title="Mosunetuzumab">Mosunetuzumab</a></li> <li><a href="/wiki/Obinutuzumab" title="Obinutuzumab">Obinutuzumab</a></li> <li><a href="/wiki/Ofatumumab" title="Ofatumumab">Ofatumumab</a></li> <li><a href="/wiki/Rituximab" title="Rituximab">Rituximab</a></li> <li><a href="/wiki/Tositumomab" title="Tositumomab">Tositumomab</a>), <i><a href="/wiki/CD30" title="CD30">CD30</a></i> (<a href="/wiki/Brentuximab_vedotin" title="Brentuximab vedotin">Brentuximab</a>), <i><a href="/wiki/CD52" title="CD52">CD52</a></i> (<a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a>)</li></ul> <ul><li><a href="/wiki/Myeloid" class="mw-redirect" title="Myeloid">myeloid</a>: <i><a href="/wiki/CD33" title="CD33">CD33</a></i> (<a href="/wiki/Gemtuzumab_ozogamicin" title="Gemtuzumab ozogamicin">Gemtuzumab ozogamicin</a>)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Amivantamab" title="Amivantamab">Amivantamab</a></li> <li><a class="mw-selflink selflink">Atezolizumab</a> (<a href="/wiki/Atezolizumab/hyaluronidase" title="Atezolizumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/wiki/Avelumab" title="Avelumab">Avelumab</a></li> <li><a href="/wiki/Axatilimab" title="Axatilimab">Axatilimab</a></li> <li><a href="/wiki/Belantamab_mafodotin" title="Belantamab mafodotin">Belantamab mafodotin</a></li> <li><a href="/wiki/Bermekimab" title="Bermekimab">Bermekimab</a></li> <li><a href="/wiki/Blinatumomab" title="Blinatumomab">Blinatumomab</a></li> <li><a href="/wiki/Cemiplimab" title="Cemiplimab">Cemiplimab</a></li> <li><a href="/wiki/Daratumumab" title="Daratumumab">Daratumumab</a></li> <li><a href="/wiki/Dinutuximab_beta" class="mw-redirect" title="Dinutuximab beta">Dinutuximab beta</a></li> <li><a href="/wiki/Dostarlimab" title="Dostarlimab">Dostarlimab</a></li> <li><a href="/wiki/Durvalumab" title="Durvalumab">Durvalumab</a></li> <li><a href="/wiki/Elotuzumab" title="Elotuzumab">Elotuzumab</a></li> <li><a href="/wiki/Enfortumab_vedotin" title="Enfortumab vedotin">Enfortumab vedotin</a></li> <li><a href="/wiki/Epcoritamab" title="Epcoritamab">Epcoritamab</a></li> <li><a href="/wiki/Inotuzumab_ozogamicin" title="Inotuzumab ozogamicin">Inotuzumab ozogamicin</a></li> <li><a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a></li> <li><a href="/wiki/Isatuximab" title="Isatuximab">Isatuximab</a></li> <li><a href="/wiki/Loncastuximab_tesirine" title="Loncastuximab tesirine">Loncastuximab tesirine</a></li> <li><a href="/wiki/Mirvetuximab_soravtansine" title="Mirvetuximab soravtansine">Mirvetuximab soravtansine</a></li> <li><a href="/wiki/Mogamulizumab" title="Mogamulizumab">Mogamulizumab</a></li> <li><a href="/wiki/Moxetumomab_pasudotox" title="Moxetumomab pasudotox">Moxetumomab pasudotox</a></li> <li><a href="/wiki/Naxitamab" title="Naxitamab">Naxitamab</a></li> <li><a href="/wiki/Necitumumab" title="Necitumumab">Necitumumab</a></li> <li><a href="/wiki/Nivolumab" title="Nivolumab">Nivolumab</a></li> <li><a href="/wiki/Olaratumab" title="Olaratumab">Olaratumab</a></li> <li><a href="/wiki/Oportuzumab_monatox" title="Oportuzumab monatox">Oportuzumab monatox</a></li> <li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a></li> <li><a href="/wiki/Polatuzumab_vedotin" title="Polatuzumab vedotin">Polatuzumab vedotin</a></li> <li><a href="/w/index.php?title=Prolgolimab&action=edit&redlink=1" class="new" title="Prolgolimab (page does not exist)">Prolgolimab</a></li> <li><a href="/wiki/Ramucirumab" title="Ramucirumab">Ramucirumab</a></li> <li><a href="/wiki/Retifanlimab" title="Retifanlimab">Retifanlimab</a></li> <li><a href="/w/index.php?title=Sabatolimab&action=edit&redlink=1" class="new" title="Sabatolimab (page does not exist)">Sabatolimab</a></li> <li><a href="/wiki/Sacituzumab_govitecan" title="Sacituzumab govitecan">Sacituzumab govitecan</a></li> <li><a href="/wiki/Serplulimab" title="Serplulimab">Serplulimab</a></li> <li><a href="/wiki/Sugemalimab" title="Sugemalimab">Sugemalimab</a></li> <li><a href="/wiki/Tafasitamab" title="Tafasitamab">Tafasitamab</a></li> <li><a href="/wiki/Talquetamab" title="Talquetamab">Talquetamab</a></li> <li><a href="/wiki/Tarlatamab" title="Tarlatamab">Tarlatamab</a></li> <li><a href="/wiki/Teclistamab" title="Teclistamab">Teclistamab</a></li> <li><a href="/wiki/Tislelizumab" title="Tislelizumab">Tislelizumab</a></li> <li><a href="/wiki/Tisotumab_vedotin" title="Tisotumab vedotin">Tisotumab vedotin</a></li> <li><a href="/wiki/Toripalimab" title="Toripalimab">Toripalimab</a></li> <li><a href="/wiki/Tremelimumab" title="Tremelimumab">Tremelimumab</a></li> <li><a href="/wiki/Zolbetuximab" title="Zolbetuximab">Zolbetuximab</a></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Tyrosine_kinase_inhibitor" title="Tyrosine kinase inhibitor">Tyrosine kinase inhibitors</a> ("-nib")</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Receptor_tyrosine_kinase" title="Receptor tyrosine kinase">Receptor tyrosine kinase</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/ErbB" title="ErbB">ErbB</a>: <i><a href="/wiki/Epidermal_growth_factor_receptor" title="Epidermal growth factor receptor">HER1/EGFR</a></i> (<a href="/wiki/Afatinib" title="Afatinib">Afatinib</a></li> <li><a href="/wiki/Aumolertinib" title="Aumolertinib">Aumolertinib</a></li> <li><a href="/wiki/Brigatinib" title="Brigatinib">Brigatinib</a></li> <li><a href="/wiki/Dacomitinib" title="Dacomitinib">Dacomitinib</a></li> <li><a href="/wiki/Erlotinib" title="Erlotinib">Erlotinib</a></li> <li><a href="/wiki/Gefitinib" title="Gefitinib">Gefitinib</a></li> <li><a href="/wiki/Icotinib" title="Icotinib">Icotinib</a></li> <li><a href="/wiki/Lazertinib" title="Lazertinib">Lazertinib</a></li> <li><a href="/wiki/Mobocertinib" title="Mobocertinib">Mobocertinib</a></li> <li><a href="/wiki/Olmutinib" title="Olmutinib">Olmutinib</a></li> <li><a href="/wiki/Osimertinib" title="Osimertinib">Osimertinib</a></li> <li><a href="/wiki/Rociletinib" title="Rociletinib">Rociletinib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a>)</li></ul> <ul><li><i>HER1/EGFR and <a href="/wiki/HER2/neu" class="mw-redirect" title="HER2/neu">HER2/neu</a></i> <ul><li><a href="/wiki/Lapatinib" title="Lapatinib">Lapatinib</a></li> <li><a href="/wiki/Neratinib" title="Neratinib">Neratinib</a></li> <li><a href="/wiki/Tucatinib" title="Tucatinib">Tucatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/BRAF_(gene)" title="BRAF (gene)">BRAF</a></i> <ul><li><a href="/wiki/Dabrafenib" title="Dabrafenib">Dabrafenib</a></li> <li><a href="/wiki/Encorafenib" title="Encorafenib">Encorafenib</a></li> <li><a href="/wiki/Vemurafenib" title="Vemurafenib">Vemurafenib</a></li></ul></li></ul> <ul><li><a href="/wiki/RTK_class_III" title="RTK class III">RTK class III</a>: <i><a href="/wiki/CD117" class="mw-redirect" title="CD117">C-kit</a> and <a href="/wiki/Platelet-derived_growth_factor_receptor" title="Platelet-derived growth factor receptor">PDGFR</a></i> (<a href="/wiki/Avapritinib" title="Avapritinib">Avapritinib</a></li> <li><a href="/wiki/Axitinib" title="Axitinib">Axitinib</a></li> <li><a href="/wiki/Masitinib" title="Masitinib">Masitinib</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Ripretinib" title="Ripretinib">Ripretinib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Toceranib" title="Toceranib">Toceranib</a>)</li> <li><i><a href="/wiki/CD135" title="CD135">FLT3</a></i> (<a href="/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a>, <a href="/wiki/Gilteritinib" title="Gilteritinib">Gilteritinib</a> (AXL, ALK, LTK))</li></ul> <ul><li><i><a href="/wiki/VEGF_receptors" class="mw-redirect" title="VEGF receptors">VEGFR</a></i> <ul><li><a href="/wiki/Axitinib" title="Axitinib">Axitinib</a></li> <li><a href="/wiki/Cediranib" title="Cediranib">Cediranib</a></li> <li><a href="/wiki/Fruquintinib" title="Fruquintinib">Fruquintinib</a></li> <li><a href="/wiki/Lenvatinib" title="Lenvatinib">Lenvatinib</a></li> <li><a href="/wiki/Nintedanib" title="Nintedanib">Nintedanib</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Regorafenib" title="Regorafenib">Regorafenib</a></li> <li><a href="/wiki/Semaxanib" title="Semaxanib">Semaxanib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Tivozanib" title="Tivozanib">Tivozanib</a></li> <li><a href="/wiki/Toceranib" title="Toceranib">Toceranib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Anaplastic_lymphoma_kinase" title="Anaplastic lymphoma kinase">ALK</a></i> <ul><li><a href="/wiki/Alectinib" title="Alectinib">Alectinib</a></li> <li><a href="/wiki/Brigatinib" title="Brigatinib">Brigatinib</a></li> <li><a href="/wiki/Ceritinib" title="Ceritinib">Ceritinib</a></li> <li><a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a></li> <li><a href="/wiki/Lorlatinib" title="Lorlatinib">Lorlatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/RET_proto-oncogene" title="RET proto-oncogene">RET</a> inhibitors:</i> <a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a> (ALK, ROS1, NTRK), <a href="/wiki/Futibatinib" title="Futibatinib">Futibatinib</a> (FGFR2), <a href="/wiki/Infigratinib" title="Infigratinib">Infigratinib</a>, <a href="/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a> (NTRK), <a href="/wiki/Pemigatinib" title="Pemigatinib">Pemigatinib</a> (FGFR), <a href="/wiki/Pralsetinib" title="Pralsetinib">Pralsetinib</a>, <a href="/wiki/Repotrectinib" title="Repotrectinib">Repotrectinib</a> (ROS1, TRK, ALK), <a href="/wiki/Selpercatinib" title="Selpercatinib">Selpercatinib</a> (VEGFR, FGFR), <a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a> (VEGFR, EGFR).</li></ul> <ul><li><i><a href="/wiki/C-Met" class="mw-redirect" title="C-Met">c-MET</a> inhibitors:</i> <a href="/wiki/Cabozantinib" title="Cabozantinib">Cabozantinib</a> (VEGFR), <a href="/wiki/Capmatinib" title="Capmatinib">Capmatinib</a>, <a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a> (ALK)</li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Non-receptor_tyrosine_kinase" title="Non-receptor tyrosine kinase">Non-receptor</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/Bcr-abl_fusion_protein" class="mw-redirect" title="Bcr-abl fusion protein">bcr-abl</a></i> <ul><li><a href="/wiki/Asciminib" title="Asciminib">Asciminib</a></li> <li><a href="/wiki/Bosutinib" title="Bosutinib">Bosutinib</a></li> <li><a href="/wiki/Dasatinib" title="Dasatinib">Dasatinib</a></li> <li><a href="/wiki/Imatinib" title="Imatinib">Imatinib</a></li> <li><a href="/wiki/Nilotinib" title="Nilotinib">Nilotinib</a></li> <li><a href="/wiki/Ponatinib" title="Ponatinib">Ponatinib</a></li> <li><a href="/wiki/Radotinib" title="Radotinib">Radotinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Src_(gene)" class="mw-redirect" title="Src (gene)">Src</a></i> (<a href="/wiki/Bosutinib" title="Bosutinib">Bosutinib</a></li> <li><a href="/wiki/Dasatinib" title="Dasatinib">Dasatinib</a>)</li></ul> <ul><li><i><a href="/wiki/Janus_kinase" title="Janus kinase">Janus kinase</a> (JAK)</i> <ul><li><a href="/wiki/Baricitinib" title="Baricitinib">Baricitinib</a></li> <li><a href="/wiki/Fedratinib" title="Fedratinib">Fedratinib</a></li> <li><a href="/wiki/Filgotinib" title="Filgotinib">Filgotinib</a></li> <li><a href="/wiki/Lestaurtinib" title="Lestaurtinib">Lestaurtinib</a></li> <li><a href="/wiki/Momelotinib" title="Momelotinib">Momelotinib</a></li> <li><a href="/wiki/Pacritinib" title="Pacritinib">Pacritinib</a></li> <li><a href="/wiki/Ruxolitinib" title="Ruxolitinib">Ruxolitinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Mitogen-activated_protein_kinase_kinase" title="Mitogen-activated protein kinase kinase">MAP2K</a> (MEK)</i> <ul><li><a href="/wiki/Binimetinib" title="Binimetinib">Binimetinib</a></li> <li><a href="/wiki/Cobimetinib" title="Cobimetinib">Cobimetinib</a></li> <li><a href="/wiki/Selumetinib" title="Selumetinib">Selumetinib</a></li> <li><a href="/wiki/Trametinib" title="Trametinib">Trametinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/EML4" title="EML4">EML4</a>-<a href="/wiki/Anaplastic_lymphoma_kinase" title="Anaplastic lymphoma kinase">ALK</a></i> <ul><li><a href="/wiki/Crizotinib" title="Crizotinib">Crizotinib</a></li> <li><a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li> <li><a href="/wiki/Lorlatinib" title="Lorlatinib">Lorlatinib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Bruton%27s_tyrosine_kinase" title="Bruton's tyrosine kinase">Bruton's</a> (BTK)</i> <ul><li><a href="/wiki/Acalabrutinib" title="Acalabrutinib">Acalabrutinib</a></li> <li><a href="/wiki/Ibrutinib" title="Ibrutinib">Ibrutinib</a></li> <li><a href="/wiki/Orelabrutinib" title="Orelabrutinib">Orelabrutinib</a></li> <li><a href="/wiki/Pirtobrutinib" title="Pirtobrutinib">Pirtobrutinib</a></li> <li><a href="/wiki/Zanubrutinib" title="Zanubrutinib">Zanubrutinib</a></li></ul></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Other</th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><i><a href="/wiki/Fusion_protein" title="Fusion protein">fusion protein</a> against <a href="/wiki/Vascular_endothelial_growth_factor" title="Vascular endothelial growth factor">VEGF</a></i> (<a href="/wiki/Aflibercept" title="Aflibercept">Aflibercept</a>)</li></ul> <ul><li><i><a href="/wiki/Proapoptotic" class="mw-redirect" title="Proapoptotic">proapoptotic</a> peptide against <a href="/wiki/ANXA2" class="mw-redirect" title="ANXA2">ANXA2</a> and <a href="/wiki/Prohibitin" title="Prohibitin">prohibitin</a></i> (<a href="/wiki/Adipotide" class="mw-redirect" title="Adipotide">Adipotide</a>)</li></ul> <ul><li><i><a href="/wiki/Exotoxin" title="Exotoxin">exotoxin</a> against <a href="/wiki/Interleukin_2" title="Interleukin 2">IL-2</a></i> (<a href="/wiki/Denileukin_diftitox" title="Denileukin diftitox">Denileukin diftitox</a>)</li></ul> <ul><li><i><a href="/wiki/MTOR_inhibitor" class="mw-redirect" title="MTOR inhibitor">mTOR inhibitors</a></i> <ul><li><a href="/wiki/Everolimus" title="Everolimus">Everolimus</a></li> <li><a href="/wiki/Ridaforolimus" title="Ridaforolimus">Ridaforolimus</a></li> <li><a href="/wiki/Sirolimus" title="Sirolimus">Sirolimus</a></li> <li><a href="/wiki/Temsirolimus" title="Temsirolimus">Temsirolimus</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Hedgehog_signaling_pathway" title="Hedgehog signaling pathway">hedgehog</a> inhibitors</i> <ul><li><a href="/wiki/Glasdegib" title="Glasdegib">Glasdegib</a></li> <li><a href="/wiki/Sonidegib" title="Sonidegib">Sonidegib</a></li> <li><a href="/wiki/Vismodegib" title="Vismodegib">Vismodegib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/CDK_inhibitor" title="CDK inhibitor">CDK inhibitors</a></i> <ul><li><a href="/wiki/Abemaciclib" title="Abemaciclib">Abemaciclib</a></li> <li><a href="/wiki/Dalpiciclib" title="Dalpiciclib">Dalpiciclib</a></li> <li><a href="/wiki/Palbociclib" title="Palbociclib">Palbociclib</a></li> <li><a href="/wiki/Ribociclib" title="Ribociclib">Ribociclib</a></li> <li><a href="/wiki/Trilaciclib" title="Trilaciclib">Trilaciclib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/KRAS" title="KRAS">KRAS</a> inhibitors</i> <ul><li><a href="/wiki/Adagrasib" title="Adagrasib">Adagrasib</a></li> <li><a href="/wiki/Sotorasib" title="Sotorasib">Sotorasib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Pi3K_inhibitor" class="mw-redirect" title="Pi3K inhibitor">Pi3K inhibitors</a></i> <ul><li><a href="/wiki/Alpelisib" title="Alpelisib">Alpelisib</a></li> <li><a href="/wiki/Copanlisib" title="Copanlisib">Copanlisib</a></li> <li><a href="/wiki/Duvelisib" title="Duvelisib">Duvelisib</a></li> <li><a href="/wiki/Idelalisib" title="Idelalisib">Idelalisib</a></li> <li><a href="/wiki/Inavolisib" title="Inavolisib">Inavolisib</a></li> <li><a href="/wiki/Parsaclisib" title="Parsaclisib">Parsaclisib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/MEN1" title="MEN1">Menin</a> inhibitors</i> <ul><li><a href="/wiki/Revumenib" title="Revumenib">Revumenib</a></li></ul></li></ul> <ul><li><i><a href="/wiki/Fibroblast_growth_factor_receptor" title="Fibroblast growth factor receptor">Fibroblast growth factor receptor</a></i> (FGFR) inhibitors</li> <li><a href="/wiki/Erdafitinib" title="Erdafitinib">Erdafitinib</a></li> <li><a href="/wiki/Futibatinib" title="Futibatinib">Futibatinib</a></li> <li><a href="/wiki/Infigratinib" title="Infigratinib">Infigratinib</a></li> <li><a href="/wiki/Pemigatinib" title="Pemigatinib">Pemigatinib</a></li></ul> <ul><li><a href="/wiki/Cabozantinib" title="Cabozantinib">Cabozantinib</a></li> <li><a href="/wiki/Capmatinib" title="Capmatinib">Capmatinib</a></li> <li><a href="/wiki/Entrectinib" title="Entrectinib">Entrectinib</a></li> <li><a href="/wiki/Gilteritinib" title="Gilteritinib">Gilteritinib</a></li> <li><a href="/wiki/Larotrectinib" title="Larotrectinib">Larotrectinib</a></li> <li><a href="/wiki/Lenvatinib" title="Lenvatinib">Lenvatinib</a></li> <li><a href="/wiki/Masitinib" title="Masitinib">Masitinib</a></li> <li><a href="/wiki/Midostaurin" title="Midostaurin">Midostaurin</a></li> <li><a href="/wiki/Nintedanib" title="Nintedanib">Nintedanib</a></li> <li><a href="/wiki/Odronextamab" title="Odronextamab">Odronextamab</a></li> <li><a href="/wiki/Pazopanib" title="Pazopanib">Pazopanib</a></li> <li><a href="/wiki/Pexidartinib" title="Pexidartinib">Pexidartinib</a></li> <li><a href="/wiki/Quizartinib" title="Quizartinib">Quizartinib</a></li> <li><a href="/wiki/Regorafenib" title="Regorafenib">Regorafenib</a></li> <li><a href="/wiki/Ripretinib" title="Ripretinib">Ripretinib</a></li> <li><a href="/wiki/Sorafenib" title="Sorafenib">Sorafenib</a></li> <li><a href="/wiki/Sunitinib" title="Sunitinib">Sunitinib</a></li> <li><a href="/wiki/Tebentafusp" title="Tebentafusp">Tebentafusp</a></li> <li><a href="/wiki/Tepotinib" title="Tepotinib">Tepotinib</a></li> <li><a href="/wiki/Vandetanib" title="Vandetanib">Vandetanib</a></li> <li><a href="/wiki/Venetoclax" title="Venetoclax">Venetoclax</a></li></ul> </div></td></tr></tbody></table></div> <div class="navbox-styles"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1236075235"></div><div role="navigation" class="navbox" aria-labelledby="PD-1_and_PD-L1_inhibitors" style="padding:3px"><table class="nowraplinks hlist mw-collapsible mw-collapsed navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1239400231"><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:PD-1_and_PD-L1_inhibitors" title="Template:PD-1 and PD-L1 inhibitors"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/w/index.php?title=Template_talk:PD-1_and_PD-L1_inhibitors&action=edit&redlink=1" class="new" title="Template talk:PD-1 and PD-L1 inhibitors (page does not exist)"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:PD-1_and_PD-L1_inhibitors" title="Special:EditPage/Template:PD-1 and PD-L1 inhibitors"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="PD-1_and_PD-L1_inhibitors" style="font-size:114%;margin:0 4em"><a href="/wiki/PD-1_and_PD-L1_inhibitors" title="PD-1 and PD-L1 inhibitors">PD-1 and PD-L1 inhibitors</a></div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Programmed_cell_death_protein_1" title="Programmed cell death protein 1"><abbr title="Programmed cell death protein 1">PD-1 inhibitors</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Programmed cell death protein 1</span></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Nivolumab" title="Nivolumab">Nivolumab</a></li> <li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a></li> <li><a href="/wiki/Cemiplimab" title="Cemiplimab">Cemiplimab</a></li> <li><a href="/wiki/Dostarlimab" title="Dostarlimab">Dostarlimab</a></li> <li><a href="/wiki/Retifanlimab" title="Retifanlimab">Retifanlimab</a></li> <li><a href="/wiki/Toripalimab" title="Toripalimab">Toripalimab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align:center;"><a href="/wiki/Programmed_death-ligand_1" class="mw-redirect" title="Programmed death-ligand 1"><abbr title="Programmed death-ligand 1">PD-L1 inhibitors</abbr></a><span class="sr-only" style="border: 0; clip: rect(0, 0, 0, 0); clip-path: polygon(0px 0px, 0px 0px, 0px 0px); height: 1px; margin: -1px; overflow: hidden; padding: 0; position: absolute; width: 1px; white-space: nowrap;">Tooltip Programmed death-ligand 1</span></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/BMS-202" title="BMS-202">BMS-202</a></li> <li><a class="mw-selflink selflink">Atezolizumab</a></li> <li><a href="/wiki/Avelumab" title="Avelumab">Avelumab</a></li> <li><a href="/wiki/Durvalumab" title="Durvalumab">Durvalumab</a></li> <li><a href="/w/index.php?title=KN035&action=edit&redlink=1" class="new" title="KN035 (page does not exist)">KN035</a></li> <li><a href="/w/index.php?title=Cosibelimab&action=edit&redlink=1" class="new" title="Cosibelimab (page does not exist)">Cosibelimab</a></li> <li><a href="/w/index.php?title=AUNP12&action=edit&redlink=1" class="new" title="AUNP12 (page does not exist)">AUNP12</a></li> <li><a href="/w/index.php?title=CA-170&action=edit&redlink=1" class="new" title="CA-170 (page does not exist)">CA-170</a></li> <li><a href="/w/index.php?title=BMS-986189&action=edit&redlink=1" class="new" title="BMS-986189 (page does not exist)">BMS-986189</a></li></ul> </div></td></tr></tbody></table></div> <div class="navbox-styles"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1236075235"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"></div><div role="navigation" class="navbox" aria-labelledby="Monoclonal_antibodies_for_tumors" style="padding:3px"><table class="nowraplinks mw-collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit"><tbody><tr><th scope="col" class="navbox-title" colspan="2"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1129693374"><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r1239400231"><div class="navbar plainlinks hlist navbar-mini"><ul><li class="nv-view"><a href="/wiki/Template:Monoclonals_for_tumors" title="Template:Monoclonals for tumors"><abbr title="View this template">v</abbr></a></li><li class="nv-talk"><a href="/wiki/Template_talk:Monoclonals_for_tumors" title="Template talk:Monoclonals for tumors"><abbr title="Discuss this template">t</abbr></a></li><li class="nv-edit"><a href="/wiki/Special:EditPage/Template:Monoclonals_for_tumors" title="Special:EditPage/Template:Monoclonals for tumors"><abbr title="Edit this template">e</abbr></a></li></ul></div><div id="Monoclonal_antibodies_for_tumors" style="font-size:114%;margin:0 4em"><a href="/wiki/Monoclonal_antibody" title="Monoclonal antibody">Monoclonal antibodies</a> for tumors</div></th></tr><tr><th scope="row" class="navbox-group" style="width:1%;text-align: center;"><a href="/wiki/Neoplasm" title="Neoplasm">Tumor</a></th><td class="navbox-list-with-group navbox-list navbox-odd hlist" style="width:100%;padding:0"><div style="padding:0 0.25em"></div><table class="nowraplinks navbox-subgroup" style="border-spacing:0"><tbody><tr><th scope="row" class="navbox-group" style="width:1%">Human</th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Adecatumumab" title="Adecatumumab">Adecatumumab</a><sup>§</sup></li> <li><a href="/wiki/Amivantamab" title="Amivantamab">Amivantamab</a></li> <li><a href="/wiki/Ascrinvacumab" title="Ascrinvacumab">Ascrinvacumab</a><sup>§</sup></li> <li><a class="mw-selflink selflink">Atezolizumab</a> (<a href="/wiki/Atezolizumab/hyaluronidase" title="Atezolizumab/hyaluronidase">+hyaluronidase</a>)</li> <li><a href="/w/index.php?title=Balstilimab&action=edit&redlink=1" class="new" title="Balstilimab (page does not exist)">Balstilimab</a><sup>†</sup></li> <li><a href="/w/index.php?title=Botensilimab&action=edit&redlink=1" class="new" title="Botensilimab (page does not exist)">Botensilimab</a></li> <li><a href="/wiki/Cixutumumab" title="Cixutumumab">Cixutumumab</a><sup>§</sup></li> <li><a href="/wiki/Conatumumab" title="Conatumumab">Conatumumab</a><sup>§</sup></li> <li><a href="/wiki/Daratumumab" title="Daratumumab">Daratumumab</a></li> <li><a href="/wiki/Drozitumab" title="Drozitumab">Drozitumab</a><sup>§</sup></li> <li><a href="/wiki/Duligotumab" class="mw-redirect" title="Duligotumab">Duligotumab</a><sup>§</sup></li> <li><a href="/wiki/Dusigitumab" title="Dusigitumab">Dusigitumab</a><sup>§</sup></li> <li><a href="/wiki/Enfortumab_vedotin" title="Enfortumab vedotin">Enfortumab vedotin</a></li> <li><a href="/wiki/Enoticumab" title="Enoticumab">Enoticumab</a><sup>§</sup></li> <li><a href="/wiki/Figitumumab" title="Figitumumab">Figitumumab</a><sup>§</sup></li> <li><a href="/wiki/Flanvotumab" title="Flanvotumab">Flanvotumab</a><sup>§</sup></li> <li><a href="/wiki/Ganitumab" title="Ganitumab">Ganitumab</a><sup>†</sup></li> <li><a href="/wiki/Glembatumumab_vedotin" title="Glembatumumab vedotin">Glembatumumab vedotin</a><sup>†</sup></li> <li><a href="/wiki/Intetumumab" title="Intetumumab">Intetumumab</a><sup>§</sup></li> <li><a href="/wiki/Ipilimumab" title="Ipilimumab">Ipilimumab</a></li> <li><a href="/wiki/Iratumumab" title="Iratumumab">Iratumumab</a><sup>§</sup></li> <li><a href="/wiki/Istiratumab" title="Istiratumab">Istiratumab</a></li> <li><a href="/wiki/Icrucumab" title="Icrucumab">Icrucumab</a><sup>§</sup></li> <li><a href="/wiki/Lexatumumab" title="Lexatumumab">Lexatumumab</a><sup>§</sup></li> <li><a href="/wiki/Lucatumumab" title="Lucatumumab">Lucatumumab</a><sup>§</sup></li> <li><a href="/wiki/Mapatumumab" title="Mapatumumab">Mapatumumab</a><sup>§</sup></li> <li><a href="/wiki/Narnatumab" title="Narnatumab">Narnatumab</a><sup>§</sup></li> <li><a href="/wiki/Necitumumab" title="Necitumumab">Necitumumab</a></li> <li><a href="/wiki/Nesvacumab" title="Nesvacumab">Nesvacumab</a><sup>§</sup></li> <li><a href="/wiki/Nivolumab" title="Nivolumab">Nivolumab</a><sup>#</sup></li> <li><a href="/wiki/Ofatumumab" title="Ofatumumab">Ofatumumab</a></li> <li><a href="/wiki/Olaratumab" title="Olaratumab">Olaratumab</a><sup>†</sup></li> <li><a href="/wiki/Panitumumab" title="Panitumumab">Panitumumab</a></li> <li><a href="/wiki/Patritumab" title="Patritumab">Patritumab</a><sup>§</sup></li> <li><a href="/wiki/Pembrolizumab" title="Pembrolizumab">Pembrolizumab</a><sup>#</sup></li> <li><a href="/wiki/Pritumumab" title="Pritumumab">Pritumumab</a><sup>§</sup></li> <li><a href="/wiki/Radretumab" title="Radretumab">Radretumab</a><sup>§</sup></li> <li><a href="/wiki/Ramucirumab" title="Ramucirumab">Ramucirumab</a></li> <li><a href="/wiki/Rilotumumab" title="Rilotumumab">Rilotumumab</a><sup>†</sup></li> <li><a href="/wiki/Robatumumab" title="Robatumumab">Robatumumab</a><sup>§</sup></li> <li><a href="/wiki/Seribantumab" title="Seribantumab">Seribantumab</a><sup>§</sup></li> <li><a href="/wiki/Sugemalimab" title="Sugemalimab">Sugemalimab</a></li> <li><a href="/wiki/Tarextumab" title="Tarextumab">Tarextumab</a><sup>§</sup></li> <li><a href="/wiki/Tisotumab_vedotin" title="Tisotumab vedotin">Tisotumab vedotin</a></li> <li><a href="/wiki/Teprotumumab" title="Teprotumumab">Teprotumumab</a><sup>†</sup></li> <li><a href="/wiki/Tovetumab" title="Tovetumab">Tovetumab</a><sup>§</sup></li> <li><a href="/wiki/Vantictumab" title="Vantictumab">Vantictumab</a><sup>§</sup></li> <li><a href="/wiki/Technetium_(99mTc)_votumumab" title="Technetium (99mTc) votumumab">Votumumab</a><sup>§</sup></li> <li><a href="/wiki/Zalutumumab" title="Zalutumumab">Zalutumumab</a><sup>†</sup></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Mouse</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Abagovomab" title="Abagovomab">Abagovomab</a></li> <li><a href="/wiki/Indium_(111In)_altumomab_pentetate" title="Indium (111In) altumomab pentetate">Altumomab pentetate</a></li> <li><a href="/wiki/Anatumomab_mafenatox" title="Anatumomab mafenatox">Anatumomab mafenatox</a></li> <li><a href="/wiki/Technetium_(99mTc)_arcitumomab" title="Technetium (99mTc) arcitumomab">Arcitumomab</a></li> <li><a href="/wiki/Bectumomab" title="Bectumomab">Bectumomab</a></li> <li><a href="/wiki/Blinatumomab" title="Blinatumomab">Blinatumomab</a></li> <li><a href="/wiki/Indium_(111In)_capromab_pendetide" title="Indium (111In) capromab pendetide">Capromab pendetide</a></li> <li><a href="/wiki/Detumomab" title="Detumomab">Detumomab</a></li> <li><a href="/wiki/Edrecolomab" title="Edrecolomab">Edrecolomab</a></li> <li><a href="/wiki/Ibritumomab_tiuxetan" title="Ibritumomab tiuxetan">Ibritumomab tiuxetan</a></li> <li><a href="/wiki/Indium_(111In)_igovomab" title="Indium (111In) igovomab">Igovomab</a></li> <li><a href="/wiki/Lilotomab" title="Lilotomab">Lilotomab</a></li> <li><a href="/wiki/Minretumomab" title="Minretumomab">Minretumomab</a></li> <li><a href="/wiki/Mitumomab" title="Mitumomab">Mitumomab</a></li> <li><a href="/wiki/Nacolomab_tafenatox" title="Nacolomab tafenatox">Nacolomab tafenatox</a></li> <li><a href="/wiki/Moxetumomab_pasudotox" title="Moxetumomab pasudotox">Moxetumomab pasudotox</a></li> <li><a href="/wiki/Naptumomab_estafenatox" title="Naptumomab estafenatox">Naptumomab estafenatox</a></li> <li><a href="/wiki/Oregovomab" title="Oregovomab">Oregovomab</a></li> <li><a href="/wiki/Pemtumomab" title="Pemtumomab">Pemtumomab</a><sup>†</sup></li> <li><a href="/wiki/Racotumomab" title="Racotumomab">Racotumomab</a></li> <li><a href="/wiki/Indium_(111In)_satumomab_pendetide" title="Indium (111In) satumomab pendetide">Satumomab pendetide</a></li> <li><a href="/wiki/Solitomab" title="Solitomab">Solitomab</a></li> <li><a href="/wiki/Taplitumomab_paptox" title="Taplitumomab paptox">Taplitumomab paptox</a></li> <li><a href="/wiki/Technetium_(99mTc)_nofetumomab_merpentan" title="Technetium (99mTc) nofetumomab merpentan">Nofetumomab merpentan</a></li> <li><a href="/wiki/Technetium_(99mTc)_pintumomab" title="Technetium (99mTc) pintumomab">Pintumomab</a></li> <li><a href="/wiki/Tenatumomab" title="Tenatumomab">Tenatumomab</a></li> <li><a href="/wiki/Tositumomab" title="Tositumomab">Tositumomab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Chimeric_antibody" class="mw-redirect" title="Chimeric antibody">Chimeric</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Amatuximab" title="Amatuximab">Amatuximab</a><sup>§</sup></li> <li><a href="/wiki/Bavituximab" title="Bavituximab">Bavituximab</a><sup>§</sup></li> <li><a href="/wiki/Brentuximab_vedotin" title="Brentuximab vedotin">Brentuximab vedotin</a></li> <li><a href="/wiki/Carotuximab" title="Carotuximab">Carotuximab</a><sup>†</sup></li> <li><a href="/wiki/Cetuximab" title="Cetuximab">Cetuximab</a></li> <li><a href="/wiki/Iodine_(131_I)_derlotuximab_biotin" title="Iodine (131 I) derlotuximab biotin">Derlotuximab biotin</a><sup>§</sup></li> <li><a href="/wiki/Dinutuximab" title="Dinutuximab">Dinutuximab</a></li> <li><a href="/wiki/Ecromeximab" title="Ecromeximab">Ecromeximab</a><sup>§</sup></li> <li><a href="/wiki/Ensituximab" title="Ensituximab">Ensituximab</a><sup>§</sup></li> <li><a href="/wiki/Futuximab" title="Futuximab">Futuximab</a><sup>§</sup></li> <li><a href="/wiki/Girentuximab" title="Girentuximab">Girentuximab</a><sup>†</sup></li> <li><a href="/wiki/Indatuximab_ravtansine" title="Indatuximab ravtansine">Indatuximab ravtansine</a><sup>§</sup></li> <li><a href="/wiki/Isatuximab" title="Isatuximab">Isatuximab</a></li> <li><a href="/wiki/Loncastuximab_tesirine" title="Loncastuximab tesirine">Loncastuximab tesirine</a></li> <li><a href="/wiki/Margetuximab" title="Margetuximab">Margetuximab</a></li> <li><a href="/wiki/Mirvetuximab_soravtansine" title="Mirvetuximab soravtansine">Mirvetuximab soravtansine</a></li> <li><a href="/wiki/Rituximab" title="Rituximab">Rituximab</a><sup>#</sup></li> <li><a href="/wiki/Siltuximab" title="Siltuximab">Siltuximab</a></li> <li><a href="/wiki/Ublituximab" title="Ublituximab">Ublituximab</a></li> <li><a href="/wiki/Zolbetuximab" title="Zolbetuximab">Zolbetuximab</a></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Humanized_antibody" title="Humanized antibody">Humanized</a></th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Abituzumab" title="Abituzumab">Abituzumab</a><sup>§</sup></li> <li><a href="/wiki/Alemtuzumab" title="Alemtuzumab">Alemtuzumab</a></li> <li><a href="/wiki/Axatilimab" title="Axatilimab">Axatilimab</a></li> <li><a href="/wiki/Belantamab_mafodotin" title="Belantamab mafodotin">Belantamab mafodotin</a></li> <li><a href="/wiki/Bevacizumab" title="Bevacizumab">Bevacizumab</a></li> <li><a href="/wiki/Bivatuzumab_mertansine" title="Bivatuzumab mertansine">Bivatuzumab mertansine</a><sup>§</sup></li> <li><a href="/wiki/Brontictuzumab" title="Brontictuzumab">Brontictuzumab</a><sup>§</sup></li> <li><a href="/wiki/Cantuzumab_mertansine" title="Cantuzumab mertansine">Cantuzumab mertansine</a><sup>§</sup></li> <li><a href="/wiki/Cantuzumab_ravtansine" title="Cantuzumab ravtansine">Cantuzumab ravtansine</a><sup>§</sup></li> <li><a href="/wiki/Cirmtuzumab" title="Cirmtuzumab">Cirmtuzumab</a></li> <li><a href="/wiki/Citatuzumab_bogatox" title="Citatuzumab bogatox">Citatuzumab bogatox</a><sup>§</sup></li> <li><a href="/wiki/Yttrium_(90Y)_clivatuzumab_tetraxetan" title="Yttrium (90Y) clivatuzumab tetraxetan">Clivatuzumab tetraxetan</a></li> <li><a href="/wiki/Cofetuzumab_pelidotin" title="Cofetuzumab pelidotin">Cofetuzumab pelidotin</a></li> <li><a href="/wiki/Dacetuzumab" title="Dacetuzumab">Dacetuzumab</a><sup>§</sup></li> <li><a href="/wiki/Demcizumab" title="Demcizumab">Demcizumab</a><sup>§</sup></li> <li><a href="/wiki/Dalotuzumab" title="Dalotuzumab">Dalotuzumab</a><sup>§</sup></li> <li><a href="/wiki/Denintuzumab_mafodotin" title="Denintuzumab mafodotin">Denintuzumab mafodotin</a><sup>§</sup></li> <li><a href="/wiki/Elotuzumab" title="Elotuzumab">Elotuzumab</a></li> <li><a href="/wiki/Emactuzumab" title="Emactuzumab">Emactuzumab</a></li> <li><a href="/wiki/Emibetuzumab" title="Emibetuzumab">Emibetuzumab</a><sup>§</sup></li> <li><a href="/wiki/Enoblituzumab" title="Enoblituzumab">Enoblituzumab</a><sup>§</sup></li> <li><a href="/wiki/Epcoritamab" title="Epcoritamab">Epcoritamab</a></li> <li><a href="/wiki/Etaracizumab" title="Etaracizumab">Etaracizumab</a><sup>§</sup></li> <li><a href="/wiki/Farletuzumab" title="Farletuzumab">Farletuzumab</a><sup>§</sup></li> <li><a href="/wiki/Ficlatuzumab" title="Ficlatuzumab">Ficlatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Flotetuzumab" title="Flotetuzumab">Flotetuzumab</a><sup>§</sup></li> <li><a href="/wiki/Gemtuzumab_ozogamicin" title="Gemtuzumab ozogamicin">Gemtuzumab ozogamicin</a></li> <li><a href="/wiki/Glofitamab" title="Glofitamab">Glofitamab</a></li> <li><a href="/wiki/Imgatuzumab" title="Imgatuzumab">Imgatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Inotuzumab_ozogamicin" title="Inotuzumab ozogamicin">Inotuzumab ozogamicin</a></li> <li><a href="/wiki/Labetuzumab" title="Labetuzumab">Labetuzumab</a><sup>§</sup></li> <li><a href="/wiki/Lifastuzumab_vedotin" title="Lifastuzumab vedotin">Lifastuzumab vedotin</a><sup>§</sup></li> <li><a href="/wiki/Lintuzumab" title="Lintuzumab">Lintuzumab</a><sup>§</sup></li> <li><a href="/wiki/Lorvotuzumab_mertansine" title="Lorvotuzumab mertansine">Lorvotuzumab mertansine</a><sup>§</sup></li> <li><a href="/wiki/Lumretuzumab" title="Lumretuzumab">Lumretuzumab</a><sup>§</sup></li> <li><a href="/wiki/Matuzumab" title="Matuzumab">Matuzumab</a><sup>§</sup></li> <li><a href="/wiki/Milatuzumab" title="Milatuzumab">Milatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Naxitamab" title="Naxitamab">Naxitamab</a></li> <li><a href="/wiki/Nimotuzumab" title="Nimotuzumab">Nimotuzumab</a><sup>†</sup></li> <li><a href="/wiki/Obinutuzumab" title="Obinutuzumab">Obinutuzumab</a></li> <li><a href="/wiki/Ocaratuzumab" title="Ocaratuzumab">Ocaratuzumab</a><sup>§</sup></li> <li><a href="/wiki/Odronextamab" title="Odronextamab">Odronextamab</a></li> <li><a href="/wiki/Otlertuzumab" title="Otlertuzumab">Otlertuzumab</a><sup>§</sup></li> <li><a href="/wiki/Onartuzumab" title="Onartuzumab">Onartuzumab</a><sup>§</sup></li> <li><a href="/wiki/Oportuzumab_monatox" title="Oportuzumab monatox">Oportuzumab monatox</a><sup>†</sup></li> <li><a href="/wiki/Parsatuzumab" title="Parsatuzumab">Parsatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Pertuzumab" title="Pertuzumab">Pertuzumab</a></li> <li><a href="/wiki/Pinatuzumab_vedotin" title="Pinatuzumab vedotin">Pinatuzumab vedotin</a><sup>§</sup></li> <li><a href="/wiki/Polatuzumab_vedotin" title="Polatuzumab vedotin">Polatuzumab vedotin</a></li> <li><a href="/wiki/Rosmantuzumab" title="Rosmantuzumab">Rosmantuzumab</a></li> <li><a href="/wiki/Rovalpituzumab_tesirine" title="Rovalpituzumab tesirine">Rovalpituzumab tesirine</a><sup>†</sup></li> <li><a href="/wiki/Sacituzumab_govitecan" title="Sacituzumab govitecan">Sacituzumab govitecan</a></li> <li><a href="/wiki/Sibrotuzumab" title="Sibrotuzumab">Sibrotuzumab</a><sup>§</sup></li> <li><a href="/wiki/Simtuzumab" title="Simtuzumab">Simtuzumab</a><sup>§</sup></li> <li><a href="/wiki/Sofituzumab_vedotin" title="Sofituzumab vedotin">Sofituzumab vedotin</a><sup>§</sup></li> <li><a href="/wiki/Yttrium_(90Y)_tacatuzumab_tetraxetan" title="Yttrium (90Y) tacatuzumab tetraxetan">Tacatuzumab tetraxetan</a><sup>§</sup></li> <li><a href="/wiki/Tigatuzumab" title="Tigatuzumab">Tigatuzumab</a><sup>§</sup></li> <li><a href="/wiki/Trastuzumab" title="Trastuzumab">Trastuzumab</a><sup>#</sup> (<a href="/wiki/Trastuzumab_deruxtecan" title="Trastuzumab deruxtecan">+deruxtecan</a> / <a href="/wiki/Trastuzumab_emtansine" title="Trastuzumab emtansine">+emtansine</a>)</li> <li><a href="/wiki/Tucotuzumab_celmoleukin" title="Tucotuzumab celmoleukin">Tucotuzumab celmoleukin</a><sup>§</sup></li> <li><a href="/wiki/Vandortuzumab_vedotin" title="Vandortuzumab vedotin">Vandortuzumab vedotin</a><sup>§</sup></li> <li><a href="/wiki/Vanucizumab" title="Vanucizumab">Vanucizumab</a><sup>§</sup></li> <li><a href="/wiki/Veltuzumab" title="Veltuzumab">Veltuzumab</a><sup>§</sup></li> <li><a href="/wiki/Vorsetuzumab_mafodotin" title="Vorsetuzumab mafodotin">Vorsetuzumab mafodotin</a><sup>§</sup></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%"><a href="/wiki/Trifunctional_antibody" title="Trifunctional antibody">Rat/mouse hybrid</a></th><td class="navbox-list-with-group navbox-list navbox-odd" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Catumaxomab" title="Catumaxomab">Catumaxomab</a></li> <li><a href="/wiki/Ertumaxomab" title="Ertumaxomab">Ertumaxomab</a><sup>§</sup></li></ul> </div></td></tr><tr><th scope="row" class="navbox-group" style="width:1%">Chimeric + humanized</th><td class="navbox-list-with-group navbox-list navbox-even" style="width:100%;padding:0"><div style="padding:0 0.25em"> <ul><li><a href="/wiki/Depatuxizumab_mafodotin" title="Depatuxizumab mafodotin">Depatuxizumab mafodotin</a><sup>†</sup></li> <li><a href="/wiki/Duvortuxizumab" title="Duvortuxizumab">Duvortuxizumab</a></li> <li><a href="/wiki/Ontuxizumab" title="Ontuxizumab">Ontuxizumab</a><sup>§</sup></li></ul> </div></td></tr></tbody></table><div></div></td></tr><tr><td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;"><div><div class="hlist"> <ul><li><sup>#</sup><a href="/wiki/WHO_Model_List_of_Essential_Medicines" title="WHO Model List of Essential Medicines">WHO-EM</a></li> <li><sup>‡</sup><a href="/wiki/List_of_withdrawn_drugs" title="List of withdrawn drugs">Withdrawn</a> from market</li> <li><a href="/wiki/Clinical_trial" title="Clinical trial">Clinical trials</a>: <ul><li><sup>†</sup><a href="/wiki/Phases_of_clinical_research#Phase_III" title="Phases of clinical research">Phase III</a></li> <li><sup>§</sup>Never to phase III</li></ul></li></ul> </div></div></td></tr></tbody></table></div> <style data-mw-deduplicate="TemplateStyles:r1130092004">.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;justify-content:center;align-items:baseline}.mw-parser-output .portal-bar-bordered{padding:0 2em;background-color:#fdfdfd;border:1px solid #a2a9b1;clear:both;margin:1em auto 0}.mw-parser-output .portal-bar-related{font-size:100%;justify-content:flex-start}.mw-parser-output .portal-bar-unbordered{padding:0 1.7em;margin-left:0}.mw-parser-output .portal-bar-header{margin:0 1em 0 0.5em;flex:0 0 auto;min-height:24px}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;flex:0 1 auto;padding:0.15em 0;column-gap:1em;align-items:baseline;margin:0;list-style:none}.mw-parser-output .portal-bar-content-related{margin:0;list-style:none}.mw-parser-output .portal-bar-item{display:inline-block;margin:0.15em 0.2em;min-height:24px;line-height:24px}@media screen and (max-width:768px){.mw-parser-output .portal-bar{font-size:88%;font-weight:bold;display:flex;flex-flow:column wrap;align-items:baseline}.mw-parser-output .portal-bar-header{text-align:center;flex:0;padding-left:0.5em;margin:0 auto}.mw-parser-output .portal-bar-related{font-size:100%;align-items:flex-start}.mw-parser-output .portal-bar-content{display:flex;flex-flow:row wrap;align-items:center;flex:0;column-gap:1em;border-top:1px solid #a2a9b1;margin:0 auto;list-style:none}.mw-parser-output .portal-bar-content-related{border-top:none;margin:0;list-style:none}}.mw-parser-output .navbox+link+.portal-bar,.mw-parser-output .navbox+style+.portal-bar,.mw-parser-output .navbox+link+.portal-bar-bordered,.mw-parser-output .navbox+style+.portal-bar-bordered,.mw-parser-output .sister-bar+link+.portal-bar,.mw-parser-output .sister-bar+style+.portal-bar,.mw-parser-output .portal-bar+.navbox-styles+.navbox,.mw-parser-output .portal-bar+.navbox-styles+.sister-bar{margin-top:-1px}</style><div class="portal-bar noprint metadata noviewer portal-bar-bordered" role="navigation" aria-label="Portals"><span class="portal-bar-header"><a href="/wiki/Wikipedia:Contents/Portals" title="Wikipedia:Contents/Portals">Portal</a>:</span><ul class="portal-bar-content"><li class="portal-bar-item"><span class="nowrap"><span typeof="mw:File"><span><img alt="icon" src="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/8px-WHO_Rod.svg.png" decoding="async" width="8" height="19" class="mw-file-element" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/12px-WHO_Rod.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/d/d6/WHO_Rod.svg/16px-WHO_Rod.svg.png 2x" data-file-width="107" data-file-height="250" /></span></span> </span><a href="/wiki/Portal:Medicine" title="Portal:Medicine">Medicine</a></li></ul></div>    </div><noscript><img src="https://login.wikimedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" width="1" height="1" style="border: none; position: absolute;"></noscript> <div class="printfooter" data-nosnippet="">Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Atezolizumab&oldid=1248728230">https://en.wikipedia.org/w/index.php?title=Atezolizumab&oldid=1248728230</a>"</div></div> <div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Drugs_developed_by_Genentech" title="Category:Drugs developed by Genentech">Drugs developed by Genentech</a></li><li><a href="/wiki/Category:Drugs_developed_by_Hoffmann-La_Roche" title="Category:Drugs developed by Hoffmann-La Roche">Drugs developed by Hoffmann-La Roche</a></li><li><a href="/wiki/Category:Monoclonal_antibodies_for_tumors" title="Category:Monoclonal antibodies for tumors">Monoclonal antibodies for tumors</a></li><li><a href="/wiki/Category:Orphan_drugs" title="Category:Orphan drugs">Orphan drugs</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:Source_attribution" title="Category:Source attribution">Source attribution</a></li><li><a href="/wiki/Category:Articles_with_short_description" title="Category:Articles with short description">Articles with short description</a></li><li><a href="/wiki/Category:Short_description_matches_Wikidata" title="Category:Short description matches Wikidata">Short description matches Wikidata</a></li><li><a href="/wiki/Category:Use_American_English_from_August_2020" title="Category:Use American English from August 2020">Use American English from August 2020</a></li><li><a href="/wiki/Category:All_Wikipedia_articles_written_in_American_English" title="Category:All Wikipedia articles written in American English">All Wikipedia articles written in American English</a></li><li><a href="/wiki/Category:Use_dmy_dates_from_September_2024" title="Category:Use dmy dates from September 2024">Use dmy dates from September 2024</a></li><li><a href="/wiki/Category:Drugs_with_non-standard_legal_status" title="Category:Drugs with non-standard legal status">Drugs with non-standard legal status</a></li><li><a href="/wiki/Category:Chemicals_that_do_not_have_a_ChemSpider_ID_assigned" title="Category:Chemicals that do not have a ChemSpider ID assigned">Chemicals that do not have a ChemSpider ID assigned</a></li><li><a href="/wiki/Category:Articles_without_EBI_source" title="Category:Articles without EBI source">Articles without EBI source</a></li><li><a href="/wiki/Category:Articles_without_InChI_source" title="Category:Articles without InChI source">Articles without InChI source</a></li><li><a href="/wiki/Category:Articles_containing_unverified_chemical_infoboxes" title="Category:Articles containing unverified chemical infoboxes">Articles containing unverified chemical infoboxes</a></li><li><a href="/wiki/Category:Drugs_that_are_a_monoclonal_antibody" title="Category:Drugs that are a monoclonal antibody">Drugs that are a monoclonal antibody</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_August_2020" title="Category:Articles with unsourced statements from August 2020">Articles with unsourced statements from August 2020</a></li><li><a href="/wiki/Category:Articles_containing_potentially_dated_statements_from_2016" title="Category:Articles containing potentially dated statements from 2016">Articles containing potentially dated statements from 2016</a></li><li><a href="/wiki/Category:All_articles_containing_potentially_dated_statements" title="Category:All articles containing potentially dated statements">All articles containing potentially dated statements</a></li><li><a href="/wiki/Category:Wikipedia_articles_in_need_of_updating_from_March_2020" title="Category:Wikipedia articles in need of updating from March 2020">Wikipedia articles in need of updating from March 2020</a></li><li><a href="/wiki/Category:All_Wikipedia_articles_in_need_of_updating" title="Category:All Wikipedia articles in need of updating">All Wikipedia articles in need of updating</a></li></ul></div></div> </div> </main> </div> <div class="mw-footer-container"> <footer id="footer" class="mw-footer" > <ul id="footer-info"> <li id="footer-info-lastmod"> This page was last edited on 1 October 2024, at 04:17<span class="anonymous-show"> (UTC)</span>.</li> <li id="footer-info-copyright">Text is available under the <a href="/wiki/Wikipedia:Text_of_the_Creative_Commons_Attribution-ShareAlike_4.0_International_License" title="Wikipedia:Text of the Creative Commons Attribution-ShareAlike 4.0 International License">Creative Commons Attribution-ShareAlike 4.0 License</a>; additional terms may apply. By using this site, you agree to the <a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Terms_of_Use" class="extiw" title="foundation:Special:MyLanguage/Policy:Terms of Use">Terms of Use</a> and <a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy" class="extiw" title="foundation:Special:MyLanguage/Policy:Privacy policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a rel="nofollow" class="external text" href="https://wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li> </ul> <ul id="footer-places"> <li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Privacy_policy">Privacy policy</a></li> <li id="footer-places-about"><a href="/wiki/Wikipedia:About">About Wikipedia</a></li> <li id="footer-places-disclaimers"><a href="/wiki/Wikipedia:General_disclaimer">Disclaimers</a></li> <li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li> <li id="footer-places-wm-codeofconduct"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Universal_Code_of_Conduct">Code of Conduct</a></li> <li id="footer-places-developers"><a href="https://developer.wikimedia.org">Developers</a></li> <li id="footer-places-statslink"><a href="https://stats.wikimedia.org/#/en.wikipedia.org">Statistics</a></li> <li id="footer-places-cookiestatement"><a href="https://foundation.wikimedia.org/wiki/Special:MyLanguage/Policy:Cookie_statement">Cookie statement</a></li> <li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Atezolizumab&mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li> </ul> <ul id="footer-icons" class="noprint"> <li id="footer-copyrightico"><a href="https://wikimediafoundation.org/" class="cdx-button cdx-button--fake-button cdx-button--size-large cdx-button--fake-button--enabled"><img src="/static/images/footer/wikimedia-button.svg" width="84" height="29" alt="Wikimedia Foundation" loading="lazy"></a></li> <li id="footer-poweredbyico"><a href="https://www.mediawiki.org/" class="cdx-button cdx-button--fake-button cdx-button--size-large cdx-button--fake-button--enabled"><img src="/w/resources/assets/poweredby_mediawiki.svg" alt="Powered by MediaWiki" width="88" height="31" loading="lazy"></a></li> </ul> </footer> </div> </div> </div> <div class="vector-settings" id="p-dock-bottom"> <ul></ul> </div><script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgHostname":"mw-web.codfw.main-5767f597fb-ct6pw","wgBackendResponseTime":163,"wgPageParseReport":{"limitreport":{"cputime":"1.162","walltime":"1.360","ppvisitednodes":{"value":8363,"limit":1000000},"postexpandincludesize":{"value":245051,"limit":2097152},"templateargumentsize":{"value":13981,"limit":2097152},"expansiondepth":{"value":18,"limit":100},"expensivefunctioncount":{"value":8,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":246170,"limit":5000000},"entityaccesscount":{"value":1,"limit":400},"timingprofile":["100.00% 1146.924 1 -total"," 36.41% 417.618 1 Template:Reflist"," 29.21% 335.056 1 Template:Infobox_drug"," 23.33% 267.562 1 Template:Infobox"," 22.43% 257.307 38 Template:Cite_web"," 12.02% 137.826 6 Template:Navbox"," 9.61% 110.225 1 Template:Targeted_cancer_therapeutic_agents"," 6.10% 69.944 1 Template:Short_description"," 5.48% 62.892 17 Template:Unbulleted_list"," 5.12% 58.727 1 Template:Chem_molar_mass"]},"scribunto":{"limitreport-timeusage":{"value":"0.614","limit":"10.000"},"limitreport-memusage":{"value":9135690,"limit":52428800}},"cachereport":{"origin":"mw-web.codfw.main-5cd4cd96d5-xs7rm","timestamp":"20241127082337","ttl":2592000,"transientcontent":false}}});});</script> <script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Atezolizumab","url":"https:\/\/en.wikipedia.org\/wiki\/Atezolizumab","sameAs":"http:\/\/www.wikidata.org\/entity\/Q20707748","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q20707748","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2015-06-01T22:27:05Z","dateModified":"2024-10-01T04:17:05Z","image":"https:\/\/upload.wikimedia.org\/wikipedia\/commons\/e\/e6\/Atezolizumab_PD-L1_5X8L.png","headline":"monoclonal anti-PD-L1 antibody"}</script> </body> </html>